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ABSTRACT 
 
Triglycerides, cholesterol, and phospholipids are essential components of all known biological 
systems. They function as energy source and starting point for many metabolic pathways. 
Therefore, lipid and lipoprotein metabolism are highly regulated processes, which ensure 
normal embryonic development and maintenance of systemic homeostasis in higher organisms.  
Lipoproteins function as transport vehicles for water-insoluble nutrients and other essential 
compounds, such as cholesterol and triglycerides, from their sites of assembly or synthesis via 
the circulation to peripheral tissues. There, a class of important biological molecules, the cell 
surface-exposed receptors, which mainly belong to the family of LDL receptor proteins, mediate 
the uptake of these lipoproteins. In the present study, I particularly focused on the interaction of 
certain of these receptors with the apolipoprotein moiety of lipoproteins. This interaction is one 
key step in the underlying functional mechanism by which lipoproteins and the corresponding 
important nutrients reach the tissues where they are needed. To gain better insights into the 
apolipoprotein-receptor interactions and their impact on lipid metabolism, these studies were 
performed in the chicken, a well-established and powerful model organism for lipid and 
lipoprotein research. 
 
One member of the apolipoprotein family with lipoprotein receptor-binding ability was found to 
be apolipoprotein A-V (apoA-V), discovered in man and mouse in 2001. ApoA-V is a regulator 
of plasma triglyceride levels, as initially demonstrated using transgenic and gene knockout 
technologies in the mouse. Many functions have been proposed for this apolipoprotein, but the 
exact mechanism of how it alters triglyceride homeostasis remains to be clarified. However, 
human apoA-V was shown to possess the capacity to bind to the LDL receptor-related protein 
(LRP1), the mosaic receptor LR11, which is also a member of the LDL receptor family, and 
sortilin, a member of the Vps10p receptor family. The ability of apoA-V to bind to cell surface 
receptors was also demonstrated in the chicken system. For instance, the major oocyte plasma 
membrane receptor LR8 binds and internalizes chicken apoA-V (ggapoA-V) into the yolk 
compartment of the germ cell. Since apoA-V was shown to be a constituent of VLDL and HDL 
plasma lipoprotein fractions, this process appears to be crucial for the efficient clearance of 
these particles from the circulation. To gain more insights into the biology of ggapoA-V 
concerning its receptor-binding ability, several chicken tissues were scanned in order to identify 
additional interaction partners of ggapoA-V.  
 
Using ligand blot analysis, the peripheral membrane protein cubilin, a receptor for various well-
studied ligands in mammals, but not yet characterized in chicken, was identified as binding 
partner of ggapoA-V. The yolk sac, which constitutes an important extraembryonic structure 
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supplying the growing embryo with nutrients, was shown to be a primary site of cubilin 
expression. The endodermal endothelial cells of the yolk sac, which face the yolk compartment, 
have been reported to express a specific set of cell surface receptors possessing high endocytic 
activity. However, detailed molecular mechanisms underlying this transport process are largely 
unknown. Therefore, the identification of a new receptor involved in endocytic processes as a 
binding partner of ggapoA-V sheds new light on the delivery of nutrients at the feto-maternal 
interface. 
 
In concert with the facts that (i) ggapoA-V is bound and subsequently endocytosed by LR8 into 
the growing oocyte, (ii) ggapoA-V is present in the yolk compartment of the germ cell, (iii) the 
protein can also be detected in the yolk sac, and (iv) ggapoA-V is bound by cubilin most 
probably present at the surface of endodermal endothelial cells of the yolk sac, the steps 
constituting the transport pathway of ggapoA-V from the maternal liver to the circulation of the 
developing embryo have now been defined.   
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ZUSAMMENFASSUNG 
 
Triglyzeride, Cholesterin und Phospholipide sind wichtige Bestandteile aller lebenden 
Organismen. Diese Substanzen dienen als Energiequelle und Ausgangsmaterial für eine große 
Anzahl an Stoffwechselvorgängen. Um zu gewährleisten, dass mit dem Lipidstoffwechsel 
verbundene Prozesse wie Embryonalentwicklung, Steroidhormonbiosynthese und 
Energiehomöostase problemlos ablaufen können, bedarf es einer komplexen und strikten 
Regulation dieser Vorgänge. 
Die Hauptaufgabe von Lipoproteinen besteht im Transport von wasserunlöslichen Stoffen wie 
Triglyzeriden und Cholesterin aus der Blutbahn in Bereiche des Körpers, an denen sie benötigt 
werden. Viele Gewebe, die auf die Aufnahme von Lipiden angewiesen sind, produzieren eine 
hoch konservierte Klasse von Lipoproteinrezeptoren, nämlich jene der Familie der LDL-
Rezeptor Proteine. Die meisten dieser Rezeptoren weisen eine hohe Endozytose-Kapazität auf, 
mit der die Aufnahme der Lipoproteinpartikel erst ermöglicht wird. 
In der vorliegenden Studie wurde die Interaktion und Bindungsaffinität der 
Apolipoproteinkomponente der Lipoproteine mit an der Zelloberfläche lokalisierten Rezeptoren 
genauer untersucht. Als Modellorganismus für die hier durchgeführten Experimente wurde das 
Huhn (Gallus gallus), ein beliebter Modellorganismus zur Erforschung des Lipidstoffwechsels, 
herangezogen. 
 
Ein Mitglied der Apolipoproteine, die Rezeptorbindungsaktivität aufweisen, ist das erst im Jahr 
2001 charakterisierte Apolipoprotein A-V (apoA-V). Im Tiermodell konnte mit apoA-V knock-out 
und transgenen Mäusen gezeigt werden, dass apoA-V großen Einfluss auf den 
Plasmatriglyzeridspiegel hat. Funktionelle Studien zeigten ein breites Wirkungsspektrum des 
Proteins auf, jedoch konnte der exakte Mechanismus mit dem apoA-V den Triglyzeridspiegel 
beeinflusst noch nicht im Detail aufgeklärt werden. 
Eine interessante Eigenschaft dieses Apolipoproteins ist seine hohe Bindungsaffinität an die 
Ligandenbindungsdomäne von Rezeptoren. Im Menschen wurden bis jetzt zwei Rezeptoren der 
LDL-Rezeptor Familie, LRP1 und LR11, und ein Protein der Vps10p-Rezeptor Familie, Sortilin, 
als Bindungspartner von apoA-V identifiziert. Diese Rezeptorbindungseigenschaft von apoA-V 
konnte auch im Huhn bestätigt werden. Der homologe Rezeptor zum menschlichen VLDL 
Rezeptor, LR8, den Hühner an der Oberfläche ihrer Oozyten exprimieren, bindet das ggapoA-V 
Protein mit hoher Affinität. Weiters konnte gezeigt werden, dass dieser Rezeptor ggapoA-V in 
den Oozyten aufnimmt. Da apoA-V ein Bestandteil von VLDL und HDL Lipoproteinfraktionen ist, 
kann die Rezeptorbindung dieses Proteins als wichtig für das Entfernen von Lipoproteinen aus 
dem Blutkreislauf und der Aufnahme dieser Partikel in verschiedenste Gewebe angesehen 
werden. Im Huhn scheint dieser Mechanismus die Aufnahme von Lipoproteinen in den 
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wachsenden Oozyten zu begünstigen. Um mehr über die Rezeptorbindungsaktivität von 
ggapoA-V zu erfahren, wollten wir neue Bindungspartner von diesem Apolipoprotein ausfindig 
machen. 
Im Dottersack, einer extraembryonalen Struktur des Hühnerembryos die den wachsenden 
Embryo mit Nährstoffen versorgt, konnte ein neuer Interaktionspartner von ggapoA-V detektiert 
werden. Das isolierte Protein konnte mittels Massenspektroskopie als Cubilin identifiziert 
werden. Cubilin, ein im Huhn bis jetzt noch nicht charakterisiertes Protein, ist ein peripheres 
Membranprotein, das häufig an der Oberfläche von Epithelzellen anzufinden ist. Dieses 
Glykoprotein bindet ein großes Spektrum an Liganden und besitzt eine gut charakterisierte 
endozytotische Aktivität. Die Entdeckung, dass Cubilin ein Protein des Dottersackes des 
Huhnes ist, ergänzt die Daten von früheren Studien. Diese zeigten, dass der Dottersack ein 
spezifisches Set von Rezptoren mit Endozytoseeigenschaften synthetisiert. Da die 
Transportprozesse, die essenziell für die Ernährung des heranwachsenden Embryos sind, noch 
nicht im Detail verstanden werden, trägt die Identifizierung von Cubilin als Bindungspartner von 
ggapoA-V im Dottersack des Huhnes zur Verbesserung des Verständnisses dieser 
Mechanismen bei. 
 
Gemeinsam mit den schon bekannten Details, dass (i) ggapoa-V vom Oozytenrezeptor LR8 
gebunden und in die Keimzelle aufgenommen wird, (ii) ggapoA-V im Dotter der Eizelle 
detektiert werden konnte, (iii) das Protein auch im extraembryonalen Dottersack anwesend ist 
und (iv) ggapoA-V von Cubilin gebunden wird, sind nun alle Abschnitte des Transportweges von 
ggapoA-V von seinem Syntheseort in der mütterlichen Leber bis hin zu den Strukturen des 
heranwachsenden Embryos bekannt.    
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1.INTRODUCTION 
1.1. Structure and Function of Lipoproteins 
Lipoproteins function as transport vehicles for water insoluble nutrients and other essential 
compounds, such as cholesterol and triglycerides, from their sites of assembly or synthesis 
through the circulation to peripheral tissues (Elkin 1997). The general structure of these large 
lipid-protein complexes is widely conserved across species, pointing to their functional 
importance.  
The inner core of lipoproteins consists of hydrophobic triglycerides and cholesterol esters, which 
are surrounded by a layer of polar lipids including free cholesterol and phospholipids, as well as 
apolipoproteins (Figure 1.1). These molecules, by exposing their hydrophilic domains to the 
surrounding milieu, ensure the transport capacity of lipoproteins.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. Schematic view of a lipoprotein particle. TG, triglycerides; CE, cholesterol esters (Picture 
from: www.peprotech.com) 
 
 
1.2. Chicken Lipoproteins 
Analogous to the situation in mammals, lipoprotein metabolism in the chicken presents an 
essential pathway for the delivery of lipids to specific tissues. The transported components are 
mainly required as energy source, for storage, and for the biosynthesis of membranes and 
steroid hormones. In addition, close similarities exist when comparing lipoprotein profiles of 
male or immature female chickens to that in mammals (Elkin 1997).  
In contrast to these similarities, the differences in the lipid transport system of mature, egg-
laying birds to that of the mammalian system are the decisive factor for making these animals 
perfect model organisms to study estrogen-induced hyperlipidemia, diet-induced 
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hypercholesterolemia and the molecular mechanisms underlying lipoprotein synthesis 
(Chapman 1980).  
In general, lipoproteins are divided into different classes according to their size, density, and the 
presence of specific apoproteins on their surface. Table 1 shows a comparison of the lipid 
content between chicken and human lipoproteins. 
 
Porto / 
Chylomicrons 
VLDL LDL HDL Lipoprotein 
composition 
LH Human LH Human LH Human LH Human 
Density 
(g/cm3) <0.94 0.94 – 1.006 1.006 – 1.063 1.063 – 1.210 
Size (nm) ~150 ~600 27 - 
54 
25 - 75 ~23.4 20 - 25 17 7 - 12 
Triglycerides ~90 ~86 61.3 ~55 11 - 
41 
7 - 11 ~8 6 - 7 
Cholesteryl 
esters 
n.d. 2 - 4 2.9 15 - 23 7 - 35 47 - 51 8 24 - 45 
Unesterified 
cholesterol 
n.d. 1 - 3 5.4 4 - 9 8 - 13 10 - 12 1.5 6 - 8 
 
Table 1.1. Comparison between chicken and human lipoproteins. 
LH = Laying hen, VLDL = very-low -density lipoprotein, LDL = low-density lipoprotein, HDL = high-
density lipoprotein. Triglycerides, cholesteryl esters, unesterified cholesterol  = % of total dry weight of 
isolated lipoprotein fractions. Values for human lipoprotein particles are from Dennis E. Vance: 
Biochemistry of Lipids, Lipoproteins and Membranes, 5th Edition, laying hen lipoprotein composition was 
taken from (Chapman 1980).  
 
1.2.1. Portomicrons 
Exogenous lipids are taken up intestinally and packaged into large, triglyceride-rich particles 
called portomicrons. These portomicrons share functional and structural features with the 
mammalian chylomicrons concerning chemical composition and size of theses particles. In 
contrast to their mammalian counterparts, portomicrons are secreted directly into the portal vein, 
consistent with the fact that the lymphatic system is only poorly developed in chickens. 
However, when chicken lipoprotein fractions were separated with different techniques in several 
studies (Chapman 1980) a separate portomicron entity could not be identified (Steinmetz and 
Schneider 1999). One reason for why portomicrons have not been isolated until now could be 
that they are immediately and efficiently endocytosed by the avian hepatic lipoprotein receptors 
such as low-density lipoprotein receptor related protein 1 (LRP1) (Schneider 1995). Moreover, 
in contrast to mammals, intestinally synthesized portomicrons also contain apoB-100, as 
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chickens lack apoB-48, which is the major apolipoprotein component of chylomicrons. However, 
to learn more about this species of lipoproteins, further studies will be necessary.  
 
1.2.2. Very-low-density lipoprotein (VLDL) 
Avian VLDL is the major carrier of hepatically derived triglycerides. The VLDL particle is 
exclusively synthesized in and secreted by the liver and provides peripheral tissues, essentially 
the laying hen’s growing oocytes, with lipids and other nutrients.  
The major apolipoprotein present on VLDL particles is apoB-100, which is also synthesized by 
the liver and is a key regulator of VLDL synthesis and secretion (Fisher and Ginsberg 2002). A 
dramatic estrogen-induced increase of VLDL synthesis and secretion occurs in female chickens 
at the onset of egg production. Concentrations reach 1000-2000 mg VLDL-triglycerides / 100ml 
serum in mature laying hens, with the majority transported to the growing oocytes (Chapman 
1980). 
 
1.2.3. Vitellogenin 
Vitellogenin is a lipophosphoglycoprotein exclusively synthesized by the liver and only present 
in egg laying birds (Chapman 1980). Like the VLDL particle, the plasma concentrations of 
vitellogenin increase dramatically via estrogen-induced hepatic synthesis. 
Vitellogenin, together with VLDL, represents the major portion of the egg’s yolk. These 
macromolecules bind to and are endocytosed into the growing oocyte by the chicken homolog 
of the mammalian VLDL receptor (VLDLR), termed LR8. Upon receptor-mediated endocytosis, 
the protein moieties of these lipoproteins are proteolytically degraded, thereby generating a 
characteristic set of polypeptides (Retzek, Steyrer et al. 1992). The catalyst for this intraoocytic 
processing of vitellogenin (and also for apoB) was found to be the lysosomal aspartyl protease 
Cathepsin D, which could be purified from oocytic yolk and preovulatory follicles (Retzek, 
Steyrer et al. 1992). The major proteolytic fragments of vitellogenin, lipovitellins and phosphitin, 
localize to membrane-enclosed endosomes in the yolk compartment termed yolk spheres, 
which reach a diameter of 140µm (Schneider, Osanger et al. 1998). Thus, the initial uptake, and 
the subsequent postendocytic processing of vitellogenin in the oocyte’s yolk compartment is 
proposed to play an important role in the reproductive effort of the hen (Retzek, Steyrer et al. 
1992).  
 
1.2.4. Low-density lipoprotein (LDL)  
A small amount of the VLDL fraction circulating through the bloodstream of chickens is lipolyzed 
to LDL via the action of lipoprotein lipase (LPL) bound to the luminal surface of endothelial cells 
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(Elkin 1997). Beside the fact that the chicken is an organism with a predominating VLDL 
lipoprotein fraction, LDL levels are in general rather low. Nevertheless, an avian LDL receptor 
(LDLR) orthologue was characterized in 2003 by Hummel et al, showing that this receptor 
prefers LDL over VLDL as ligand (Hummel, Lynn et al. 2003). The chicken LDLR shows the 
same structural features as its mammalian counterpart (Hummel, Lynn et al. 2003) 
demonstrating that the protein has been conserved in evolution. Differences can be seen when 
comparing avian and human LDLR expression levels, being rather low in the avian species 
(Schneider 2007). Furthermore, the delivery of LDL-derived cholesterol seems to be exclusively 
relevant in steroidogenic tissues, such as the adrenal and the ovary, which are also the main 
expression sites of the avian LDL receptor (Schneider 2007). 
 
1.2.5. High-density lipoprotein (HDL) 
HDL represents, besides VLDL, the main class of lipoprotein particles that are synthesized in 
and secreted by the liver and possibly certain peripheral tissues (Hermier 1997). The major 
apolipoprotein present on the HDL particle, apoA-I, is also synthesized almost exclusively by 
the liver. One characteristic feature of the HDL fraction is that it can be subdivided into several 
subclasses containing HDL1, HDL2, and HDL3, where HDL1 is the largest and least dense 
particle. The nascent, discoidal HDL fraction, which is secreted by the liver into the circulation 
contains about 1-4 copies of apoA-I. ApoA-I, located on the surface of the HDL particle, 
recovers cholesterol from the periphery to incorporate it into HDL. The enzyme 
lecithin:cholesterol acyltransferase (LCAT), which is also bound to the HDL particle, converts 
this cholesterol into insoluble cholesteryl-esters, which form the core of the growing HDL 
particle. Finally, these lipid-enriched HDL particles (mainly HDL1) become selectively 
internalized by the liver, thereby acting as the main mediators of the reverse cholesterol 
transport. Furthermore, the HDL particles can provide steroidogenic tissues like adrenals or the 
ovary with cholesterol. 
In contrast to avian VLDL, the synthesis of apoA-I and HDL particles appears not to be induced 
by estrogen in the chicken. Rather, there is evidence that the apoA-I expression is reduced at 
the onset of egg laying (Schneider 1995). Nevertheless, it was shown that a significant amount 
of HDL particles are present in the egg’s yolk (Vieira, Vieira et al. 1995). Furthermore, due to 
the fact that a specific oocyte plasma membrane receptor for the uptake of HDL particles could 
not be detected, an alternative process such as bulk phase uptake via a general endocytic 
activity of the oocyte plasma membrane has been proposed (Schneider 1995; Vieira, Vieira et 
al. 1995). 
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1.3. Apolipoproteins of the Chicken  
Apolipoproteins present the protein moiety of lipoproteins. Each lipoprotein class is endowed 
with a specific set of apolipoproteins. These proteins are localized on the surface of the 
lipoprotein particles and are responsible for the very distinct features of each lipoprotein class. 
Table 2 shows the basic properties of chicken apolipoproteins characterized so far and their 
association with different lipoprotein classes.  
 
Apolipoprotein Chromosomal location 
Molecular 
weight 
(kDa) 
Primary 
source 
Lipoprotein 
association Function 
ApoA-I 24 28 Liver, Intestine, Kidney HDL 
Reverse chol. 
transport, LCAT 
activator 
ApoA-IV 24 38 Liver, Intestine Not known Lipid binding, LCAT activation 
ApoA-V 24 40 Liver, Intestine VLDL, lipid free, possibly HDL 
Binds LR8, 
LRP380, TG 
modulation 
ApoB-100 3 ~500 Liver, Intestine, Kidney 
VLDL+IDL, LDL, 
“light” HDL 
(kidney) 
Controls VLDL 
secretion, 
LDLR + LR8 
ligand 
ApoC-III 24 9 Liver, Kidney, Fat Not known 
Lipase 
modulator 
ApoVLDL-II 1 15 (homodimer) Liver VLDL Inhibition of LPL 
 
Table1.2. Chicken apolipoproteins. 
 
1.3.1. Apolipoprotein A-I 
Apolipoprotein A-I, whose gene is a member of the APOA1/C3/A4/A5 gene cluster, is the major 
apolipoprotein of the HDL particle and well described in mammals as well as in chickens. The 
galline, mature apoA-I protein comprises 240 amino acids and has a molecular weight of about 
28 kDa (Rajavashisth, Dawson et al. 1987). Although the protein shows only 48% sequence 
identity with mammalian apoA-I, the two proteins share structural and functional similarities. 
Both proteins are enriched in alpha helical structures at their C-terminus, a hallmark of many 
known apolipoproteins. Furthermore, it was shown that chicken apoA-I is capable in mobilizing 
cellular cholesterol, which subsequently is available for the esterification via LCAT, present on 
HDL particles. In agreement with the fact that chicken apoA-I has two potential lipid binding 
sites (residues 43-63 at its C-terminus, and residues 189-240 at its N-terminus), the protein has 
the ability to transform phospholipid vesicles into discoidal bilayer structures in vitro (Kiss, Ryan 
et al. 2001).  
Analysis of the expression patterns of chicken apoA-I by Northern blotting revealed the 
presence of apoA-I mRNA in the liver, intestine, brain, adrenals, kidney, heart and muscle 
(Rajavashisth, Dawson et al. 1987). This expression pattern is very different to that of human 
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apoA-I, which is only expressed in the liver and intestine. Interestingly, the mRNA distribution of 
chicken apoA-I resembles that of mammalian apoE (Rajavashisth, Dawson et al. 1987). 
In contrast to many other chicken apolipoproteins, a decrease of apoA-I expression was found 
when a chicken hepatoma cell line was treated with estrogen in cell culture experiments 
(Hermann, Foisner et al. 2003).  
Furthermore, chicken granulosa cells (GC), which surround the growing oocyte, produce apoA-
I. This was shown in (Hermann, Lindstedt et al. 1998), where cultured GC’s secreted apoA-I 
containing particles of high density (< 1.2 g/cm3) into the medium. These apoA-I containing 
particles might support the rapidly growing germ cell by the transfer of lipids directly to the 
plasma membrane of the oocyte. Another possible mechanism of these apoA-I containing 
particles is the delivery of cholesteryl esters to the steroid-producing cells of the theca layer 
(Hermann, Lindstedt et al. 1998).  
 
1.3.2. Apolipoprotein A-IV 
As another product of the APOA1/C3/A4/A5 gene cluster, apoA-IV is one of the best 
characterized chicken apolipoproteins. The gene is located on chicken chromosome 24 and the 
apoA-IV gene is transcribed in the same direction as those specifying apoA-I and apoA-V.  
(Steinmetz and Schneider 1999). The mature chicken apoA-IV protein contains 347 amino 
acids, has a molecular weight of about 38 kDa and lacks cysteine residues. The primary 
expression sites of the avian apoA-IV gene are liver and intestine, as revealed by Northern Blot 
analysis (Steinmetz and Schneider 1999). The protein contains alpha helical structures, has 
lipid binding affinity and is capable of activating LCAT in vitro (Steinmetz and Schneider 1999). 
Although the human apoA-IV protein shows about 57% sequence identity with its avian 
counterpart, structural and also functional features seem to be different. Chicken apoA-IV is 
very hydrophobic and also is more acidic than its mammalian orthologue. The chicken apoA-IV 
protein is truncated at position 346 and thus lacks the mammalian C-terminal EQQQ motif. In 
2000, Weinberg et al. showed with Fourier transform plots and Circular dichroism spectroscopy 
that chicken apoA-IV structurally and biophysically seems to be more related to human apoA-I 
than to human apoA-IV (Weinberg, Cook et al. 2003). They suggested that apoA-IV originates 
from a duplication of the apoA-I gene as a result of evolutionary changes in the genomic 
structure.  
Only little is known about the association of chicken apoA-IV with lipoproteins. Its mammalian 
orthologue is found to be an apoprotein of chylomicrons and HDL with a high ability to activate 
LCAT. Due to its expression in the liver, one function of avian apoA-IV could be that it 
associates with portomicrons and facilitates the uptake of these particles into the liver. In 
addition, apoA-IV as a constituent of HDL is thought to be involved in the mobilization of 
cholesterol from peripheral cells. Therefore, apoA-IV could be important in providing the 
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growing oocyte with cholesterol or in mediating the reverse cholesterol transport back to the 
liver (Steinmetz and Schneider 1999).   
 
1.3.3. Apolipoprotein B 
Apolipoprotein B (apoB) is unique among the plasma apolipoproteins because of its extremely 
high overall hydrophobicity, high molecular weight (~500 kDa) and inability to transfer between 
lipoproteins of different classes (Kane 1983). In humans, apoB occurs in two forms, apoB-100 
and apoB-48. The larger apoB-100 consits of 4536 amino acids, whereas apoB-48, arising by 
cotranscriptional mRNA editing, corresponds to the N-terminal 48% of apoB-100 (Chen, Habib 
et al. 1987). In humans, apoB-100 is predominantly synthesized in the liver, whereas apoB-48 is 
mainly expressed in the intestine (Glickman, Rogers et al. 1986). 
In contrast to that, in the chicken the apoB-100 mRNA is unedited. Therefore, these animals 
produce apoB-100 only. The chicken apoB-100 mRNA has approximately the same size as the 
mammalian apoB transcript (~14kb), present at high levels in the liver and intestine. Unlike in 
mammals, the chicken apoB-100 mRNA is also found in the kidney. The hepatic mRNA levels 
increase rapidly following treatment with estrogen. 
As the major protein component of VLDL, apoB-100 is important for the structural and functional 
integrity of the lipoprotein particle. For example, apoB, together with the microsomal triglyceride 
transfer protein (MTP) is essential for the assembly and secretion of VLDL particles. MTP 
functions in transferring lipids to apoB during its translation. Furthermore, MTP translocates 
triglycerides into the endoplasmatic reticulum (ER), where apoB-free lipid droplets form. These 
droplets associate with the nascent apoB-containing particles to form mature VLDL lipoproteins 
(Davidson and Shelness 2000). The major portion of hepatically synthesized VLDL is taken up 
by the major oocyte receptor LR8 into the growing germ cell (Bujo, Hermann et al. 1994). ApoB-
100, present on these VLDL particles, mediates the receptor binding of VLDL (Nimpf, George et 
al. 1988) leading to subsequent endocytosis. Like vitellogenin, apoB-100 undergoes partial 
proteolytic degradation after the uptake into the growing oocyte, mediated by the protease 
Cathepsin D (Retzek, Steyrer et al. 1992). This proteolysis leads to a specific pattern of apoB-
fragments in the oocyte’s yolk. However, this degradation was shown not to affect the 
recognition of yolk VLDL by LR8 (Nimpf, Radosavljevic et al. 1989), which is also expressed on 
the surface of endodermal endothelial cells (EEC’s) of the embryonic yolk sac (Hermann, 
Mahon et al. 2000). Therefore it is proposed that VLDL particles from the yolk are delivered to 
the EEC layer of the yolk sac by an endocytic process. Following uptake, the yolk VLDL 
particles are degraded in the EEC’s and most probably used for subsequent reassembly and/or 
resynthesis of embryonic VLDL particles. That reassembly of VLDL occurs in the EEC layer is 
supported by (i) the presence of apoB mRNA and the MTP protein in the yolk sac (Hermann, 
Mahon et al. 2000), and (ii) the absence of apoVLDL-II from VLDL in the embryonic circulation. 
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The apoB production in chicken kidney was measured to be approximately 30% of that of the 
liver (Tarugi, Ballarini et al. 1998). Whereas the hepatic apoB is only present on VLDL and LDL 
lipoprotein particles, renal apoB was shown to be associated with VLDL, LDL and also with HDL 
fractions (Tarugi, Ballarini et al. 1998). Unlike in the liver, estrogen treatment has no effect on 
the synthesis of apoB in the kidney, nor does it induce the expression of the hepatic VLDL-
associated lipoprotein lipase inhibitor apoVLDL-II (Kirchgessner, Heinzmann et al. 1987; Lazier, 
Wiktorowicz et al. 1994).  
However, whether renal synthesis of apoB-containing lipoproteins contributes to the regulation 
of plasma lipoprotein levels in the chicken remains to be elucidated.   
 
1.3.4. Apolipoprotein C-III  
Only very little is known about apolipoprotein C-III (apoC-III) in the chicken. As the product of 
another member of the APOA1/C3/A4/A5 gene cluster, apoC-III comprises 92 amino acids, 
including a 21 amino acid signal peptide. The protein has a calculated molecular weight of 9 
kDa and shares 32% sequence identity with human apoC-III. The expression of chicken apoC-
III is mainly restricted to the liver, with low amounts of apoC-III mRNA also detected in the 
kidney and fat as shown by Northern blot analysis (Nikolay 2006).  
Detailed studies in the mammalian system revealed that plasma apoCIII levels are positively 
correlated with plasma triacylglycerol concentrations and that the protein is a direct or indirect 
inhibitor of LPL. To gain better insights into the biology of chicken apoC-III, further studies have 
to be conducted.    
 
1.3.5. Apolipoprotein VLDL-II 
In the laying hen, the second major protein component of the VLDL particle besides apoB is 
apolipoprotein VLDL-II (apoVLDL-II). The laying hen’s serum contains about 1.5 mg/ml VLDL 
protein, whereof approximately 40-60% corresponds to apoVLDL-II. Therefore, the serum 
concentration of apoVLDL-II ranges from 600 to 900 µg/ml in the laying hen (Schneider, Carroll 
et al. 1990). Located on chicken chromosome 1, the gene for apoVLDL-II encodes a 9.5 kDa 
protein which associates via a single cysteine residue into a disulfide-bonded homodimer. 
Moreover, apoVLDL-II is exclusively present on VLDL particles of laying hens, but is not found 
in roosters or immature hens (Schneider, Carroll et al. 1990). 
With the onset of egg laying, massive amounts of VLDL particles are transported from the liver 
to the growing oocyte. Interestingly, it was found that these particles remain unaffected during 
the transport through the circulation, since no appreciable hydrolysis of triglycerides occurs. The 
presence of active LPL on the surface of capillary endothelial cells, and in addition, the 
synthesis of LPL by the granulosa cell layer of the chicken follicle, make the fact that the lipid 
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composition of yolk VLDL particles resemble that of the VLDL fraction present in the circulation 
an even more astounding event.  
This protection of the VLDL particles against lipolysis on their way from the liver to the growing 
oocyte was found to be mediated by apoVLDL-II, which is a potent inhibitor of LPL (Schneider, 
Carroll et al. 1990). Therefore, the inhibition of LPL in the periphery leads to an accumulation of 
triglycerides in the female germ cell. 
The mature form of chicken apoVLDL-II present on VLDL particles is a homodimer. In contrast, 
apoVLDL-II from the Japanese quail (Coturnix coturnix), where the cysteine at residue 75 is 
replaced by a tryptophan, is associated with VLDL as a monomer (MacLachlan, Steyrer et al. 
1996). Nevertheless, dimerization of the protein is not required for exerting its inhibitory effect 
since both avian proteins markedly inhibit the activity of LPL (MacLachlan, Steyrer et al. 1996). 
 
1.3.6. Mammalian Apolipoprotein A-V  
Identification and genomic organization 
The gene encoding apolipoprotein A-V (apoA-V) was first identified in 2001 by Pennacchio et al 
(Pennacchio, Olivier et al. 2001). They looked for so far unidentified evolutionary conserved 
sequences in the well studied APOA1/C3/A4 gene cluster on human chromosome 11q23 by 
comparing about 200 kilo base pairs (kbp) of mouse and orthologous human DNA (Pennacchio, 
Olivier et al. 2001). A well conserved sequence stretch, located ~30 kilobases (kb) proximal to 
the APOA1/C3/A4 gene cluster (Figure 1.2), was identified as a four exons containing ~1100 
base pair (bp) open reading frame. This human genomic locus encodes a 366 amino acid 
protein including an amino terminal signal peptide with 71% sequence identity to its mouse 
counterpart. Furthermore, it was shown that murine apoA-V shares the greatest sequence 
homology with apoA-IV (24% identical and 49% similar). Northern blot analysis from several 
human and mouse tissues using APOA5 cDNA probes revealed two transcripts about 1.3 and 
1.9 kb, predominantely present in the liver of both species (Pennacchio, Olivier et al. 2001). 
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Figure 1.2. ApoA-V is a member of the APOA1/C3/A4 gene cluster on human chromosome 11. 
The gene is composed of four exons (E1, E2a, E2b, E3, E4), a 5’ untranslated region (5’UTR, grey 
boxes) and an alternative 3’UTR. The protein coding exons (E2b, E3, E4) are marked in blue. ATG and 
TGA represent the start and stop codons, respectively. 
 
Biochemical and structural properties of apoA-V  
ApoA-V, identified as a family member of the exchangeable apolipoproteins, shares common 
structural motifs with this group of proteins. Human apoA-V is nearly insoluble at neutral pH and 
lacks common sites for glycosylation (Beckstead, Oda et al. 2003). The amino acid composition 
of apoA-V is similar to that found in other apolipoproteins, whereas far-UV circular dichroism 
(CD) studies of apoA-V revealed that the protein is composed of 32% alpha helix, 33% beta 
sheet, 16% beta turn and 18% random coil in the lipid-free form (Beckstead, Oda et al. 2003). 
Thus, unlike most other apolipoproteins, apoA-V displays significant amounts of beta structure.  
Furthermore, apoA-V binds to dimyristoylphosphatidylcholine (DMPC) vesicles, thereby showing 
solubility at neutral pH and an increase in alpha helical structure up to ~50%.  
At least 3 alpha helices were shown to be located in the N-terminal region (amino acids 1-146) 
of the apoA-V protein (Wong, Beckstead et al. 2008), whereas the C-terminal part of the protein 
was reported to possess strong lipid binding activity (Beckstead, Wong et al. 2007).  
 
APOA5 gene regulation 
In general, the plasma levels of apoA-V are low. Van der Vliet et al (van der Vliet, Sammels et 
al. 2001) reported concentrations about 1µg/ml in rodents’ plasma, whereas Ishihara et al 
(Ishihara, Kujiraoka et al. 2005) and O’Brien et al (O'Brien, Alborn et al. 2005) observed plasma 
levels of 0.1–0.4µg/ml in humans. Thus, plasma levels of apoC-III and apoA-I are approximately 
6– and 50–fold higher than those of apoA-V, respectively (Hahne, Krempler et al. 2008). 
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APOA5 gene expression is regulated by several transcription factors. The peroxisome 
proliferator activated receptor alpha (PPARA), the hepatocyte nuclear factor 4 alpha (HNF4A), 
and the upstream regulatory factor 1 (USF1) contribute to an upregulation of apoA-V mRNA 
levels (Prieur, Coste et al. 2003; Nowak, Helleboid-Chapman et al. 2005; Prieur, Schaap et al. 
2005). Moreover, apoA-V mRNA levels were elevated in rats after partial hepatectomy (van der 
Vliet, Sammels et al. 2001). In contrast, liver X receptor alpha (LXRA) and insulin (by 
phosphorylation of USF1) were shown to down-regulate APOA5 transcription (Nowak, 
Helleboid-Chapman et al. 2005; Jakel, Nowak et al. 2006). In addition, by simulating a condition 
of acute inflammation in a mouse model, a significant degradation of apoA-V mRNA was 
observed  in response to the proinflammatory cytokines tumor necrosis factor alpha (TNF-α) 
and interleukin-1beta (IL-1β) (Becker, Schomburg et al. 2006). 
 
Physiological role of apoA-V 
ApoA-V is a regulator of plasma triglyceride (TG) levels. This was initially demonstrated using 
mouse transgenic and gene knockout technologies. Mice overexpressing a human APOA5 
transgene showed decreased plasma TG levels of about 70% compared to their control 
littermates. In contrast, apoA-V knockout mice showed a fourfold increase of plasma TG’s 
(Pennacchio, Olivier et al. 2001). These data are in sharp contrast to those observed for apoC-
III knockout and transgenic mice, indicating that these two proteins have antagonizing effects on 
plasma TG levels. Also some single nucleotide polymorphisms (SNP’s) in the APOA5 gene 
show a strong correlation with plasma TG levels in humans.  
Furthermore, apoA-V associates with lipoprotein particles. The protein is present in VLDL, HDL 
and chylomicrons, but not in the LDL fraction of human lipoproteins (O'Brien, Alborn et al. 
2005). Interestingly, in the apoA-V knockout mouse, the synthesis of VLDL particles was 
increased. Thus, it was proposed that apoA-V may act as an inhibitor of VLDL–triglyceride 
production (O'Brien, Alborn et al. 2005).   
In a study of Merkel et al in 2005 (Merkel, Loeffler et al. 2005) it was found that LPL, bound to 
heparan sulfate proteoglycans (HSPG’s), was activated by apoA-V, but the exact underlying 
molecular mechanism remains to be elucidated. Moreover, apoA-V was reported to associate 
with lipid droplets in a rat hepatoma cell line (Shu, Ryan et al. 2008). These findings, together 
with the fact that partial hepatectomy in rats increases apoA-V transcription (van der Vliet, 
Sammels et al. 2001) as well as induces lipid droplet formation (Turro, Ingelmo-Torres et al. 
2006) indicate new functional properties of apoA-V.  
 
Receptor binding 
Recent reports have demonstrated a high capacity of apoA-V to bind various cell surface 
receptors. In experiments using surface plasmon resonance (SPR) it was shown that lipid free 
as well as DMPC–complexed apoA-V interacts with LRP1, the mosaic type-1 receptor 
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LR11/SorLA, and sortilin (Nilsson, Lookene et al. 2007; Nilsson, Christensen et al. 2008). Cell 
experiments showed that the binding of apoA-V to LR11 and sortilin resulted in rapid 
internalization of the protein into intracellular compartments. Moreover, apoA-V was able to 
enhance the binding of chylomicrons to LRP1-covered sensor chips (Nilsson, Lookene et al. 
2007). The binding affinity of apoA-V to these receptors was decreased in the presence of 
heparin.  
Together, these findings show that apoA-V binds to receptors possessing ligand binding 
domains present in proteins of the LDLR family (LRP1, LR11/SorLA) and to receptors of the 
Vps10p family (Sortilin).  
In addition to the receptor binding ability of apoA-V, (Gin, Beigneux et al. 2007) reported that 
DMPC disks containing apoA-V bound to the glycosylphosphatidylinositol-anchored high- 
density lipoprotein–binding protein 1 (GPIHBP1), which is found exclusively on the luminal 
surface of endothelial cells (Gin, Beigneux et al. 2007). 
 
1.3.7. Chicken Apolipoprotein A-V   
The gene encoding chicken apolipoprotein A-V (ggapoA-V) is located on chicken chromosome 
24 in a gene cluster that also contains APOA1 and APOA4 (Dichlberger, Cogburn et al. 2007). 
Like its human and mouse counterpart, ggapoA-V is synthesized as a precursor protein 
including an amino terminal signal peptide. This precursor protein comprises 351 amino acids 
and shows a high degree of conservation from chicken to mammals (42% identities between the 
chicken and human protein and 39% between chicken and murine apoA-V (Dichlberger, 
Cogburn et al. 2007)).  
The mature protein comprises 328 residues and has a molecular mass of about 40 kDa. Using 
Western blot analysis, the ggapoA-V protein could be detectecd in chicken plasma, where it 
was found in the VLDL and in the d > 1.21 (HDL) fractions. The protein is also present in 
several tissues of the chicken, including the liver, small intestine, kidney, brain, and ovarian 
follicles (Dichlberger, Cogburn et al. 2007). 
As its mammalian counterpart, ggapoA-V shows high affinity binding properties to cell surface 
receptors, as demonstrated for the main chicken oocyte receptor LR8 (Dichlberger, Cogburn et 
al. 2007). Interaction of ggapoA-V with LR8 is proposed to play an important role in the delivery 
of TG-rich lipoproteins to the growing oocytes of the chicken. In addition, ggapoA-V binds to 
another, chicken specific, member of the LDLR family termed LRP380 (Dichlberger A., 
unpublished data). This large protein is also proposed to be an oocyte specific, membrane 
associated receptor. 
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1.4. Binding Partners of Apolipoprotein A-V 
The high capacity of apoA-V to bind endocytic receptors was shown in several studies using 
various methods. Until now, four proteins have been identified which show high-affinity 
interaction with this apolipoprotein, all of them acting as receptors with high endocytic activity. 
Figure 1.3 shows the overall structural composition of the binding partners of apoA-V. 
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Figure 1.3. Thus far identified binding partners of apoA-V. ApoA-V was shown to interact with LR8, 
LR11 and LRP1, which are members of the LDLR family, and with sortilin, a member of the Vps10p 
receptor family.  
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1.4.1. LR8 
A 95 kDa chicken plasma membrane receptor, predominantly expressed by the chicken oocyte, 
was initially identified as the receptor for the major components of yolk, VLDL and VTG (Stifani, 
Barber et al. 1990). Molecular characterization of this protein revealed a close structural 
relationship to the LDLR. Therefore, this protein was identified as a member of the LDLR 
supergene family, characterized by the presence of preserved structural domains. In order of 
appearance from the carboxy terminus, these structural domains of the receptor are (i) a 
cytoplasmic tail of about 50 amino acids containing the internalization sequence Asn-Pro-Xaa-
Tyr (NPXY) which is essential for the targeting of the receptor into clathrin-coated vesicles; (ii) a 
short transmembrane stretch consisting of ~ 20 hydrophobic amino acids; (iii) the O-linked 
sugar domain, enriched in O-glycosylated serine and threonine residues; (iv) the epidermal 
growth factor (EGF) precursor homology domain comprising about 400 amino acids. This 
domain is composed of three repeats with high homology to EGF and a six-bladed beta 
propeller, with each of these six stretches carrying the consensus sequence motif Tyr-Trp-Thr-
Asp (YWTD); (v) the ligand binding domain, exposed at the amino terminus of the protein which 
consists of approximately 40 amino acid residues, is highly enriched in cysteine residues and 
negatively charged amino acids. Chicken LR8 contains eight such ligand binding repeats (LA-
repeats), in contrast to the seven LA-repeats of the LDLR (Schneider 2007). Eight LA-repeats 
are also a hallmark for the group of the mammalian VLDL receptors (VLDLR). Therefore, 
chicken LR8 represents the functional homolog to the mammalian VLDLR.  
The gene for LR8 is located on the chicken sex chromosome Z (Bujo, Hermann et al. 1994) and 
the sequence shows 84% identity to its human counterpart. Chicken LR8, which shows high 
binding affinity for its ligands apoB present on VLDL particles (Nimpf, Radosavljevic et al. 1989) 
and the lipovitellin domain of VTG (Stifani, Barber et al. 1990), is essential for oocyte growth 
and development. The functional importance of the receptor is demonstrated by a non-laying 
chicken strain (Restricted Ovulator = R/O) carrying a single point mutation in the LR8 gene. 
Because VLDL-associated triglycerides are not deposited into the oocyte, these chickens 
develop severe hyperlipidemia and atherosclerotic lesions. 
The predominant expression of LR8 in the chicken oocyte resembles that of the mammalian 
VLDLR, which also appears to be expressed in ovarian tissues (Webb, Patel et al. 1994). 
Besides its ligands apoB and VTG, LR8 was shown to bind the 39 kDa receptor-associated 
protein (RAP). RAP acts as a chaperone in the endoplasmic reticulum and binds to the ligand 
binding domains of all members of the LDLR family in intracellular compartments. This binding 
is crucial for the correct folding of the receptor proteins and prevents premature intracellular 
binding of their ligands (Stifani, Barber et al. 1990).  
Furthermore, like all VLDLRs, LR8 exists in two different forms, LR8- and LR8+, generated by 
differential splicing (Hermann, Mahon et al. 2000). LR8-, which lacks the O-linked sugar domain 
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is predominantly expressed by the chicken oocyte. In contrast, LR8+ is the major form 
expressed by somatic cells (Hermann, Mahon et al. 2000), although at very low levels 
compared to those of LR8- in the oocytes. 
 
1.4.2. Sortilin 
Sortilin is a glycoprotein of approximately 100 kDa first isolated from human brain extracts by 
using RAP affinity chromatography (Petersen, Nielsen et al. 1997). The gene for human sortilin 
maps to chromosome 1p and encodes an 833-amino acid type I receptor. Sortilin was found to 
be expressed in several tissues including the brain, placenta, skeletal muscle, heart, spinal cord 
and testis (Mazella 2001). The protein shows no homology to the LDL receptor family members. 
Therefore, sortilin represents the first RAP binding partner not related to the LDL receptor 
family.  
Furthermore, sortilin is the receptor for the neuropeptide neurotensin, which exerts various 
functions in mammals. In addition to its functional importance in the brain, neurotensin induces 
hypotension, decreases gastric acid secretion, and activates lipid digestion in the periphery 
(Mazella 2001). Sortilin was also identified as a major component of glucose transporter (Glut)-4 
containing vesicles in rat adipocytes (Lin, Pilch et al. 1997). 
The characteristic structural motif of sortilin is a cysteine-rich domain, homologous to a domain 
in the yeast vacuolar protein sorting 10 protein (Vps10p), which represents the extracellular or 
luminal part of the protein (Mazella 2001). In yeast, the protein is a sorting receptor for 
carboxypeptidase Y, located mainly in the trans-Golgi network (TGN). Figure 1.4 shows a 
comparison between the yeast sorting receptor Vps10p and human sortilin. 
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Figure 1.4. Comparison of the yeast 
sorting receptor Vps10p and human 
sortilin. Sortilin is composed of one Vps10p 
domain which shapes the luminal/ 
extracellular part of the protein. The most 
conserved stretch of  the Vps10p domain, 
highly enriched in cysteine residues, is 
illustrated in blue. Moreover, sortilin contains 
6 additional cysteines (lines), which are 
located in the extracellular region of the 
protein (Figure adapted and modified from 
(Petersen, Nielsen et al. 1997)).  
  
 
 
 
 
 
 
 
The Vps10p domain is a ~ 700-amino acid module that functions as a protein interaction motif 
(Willnow, Petersen et al. 2008). The yeast Vps10p protein contains two such domains with an 
overall identity between them of 20%, whereas sortilin harbours only one, in agreement with the 
fact that the luminal/extracellular domain of human sortilin consists of exactly 726 amino acids 
(Petersen, Nielsen et al. 1997; Willnow, Petersen et al. 2008). Alignment of sortilin with the 
yeast Vps10 protein revealed a stretch of 140 amino acids with high homology between the two 
proteins. This region, located in the C-terminus of sortilin, contains 10 cysteine residues. 
Interestingly, these cysteines show an almost identical spacing in sortilin and Vps10p (Petersen, 
Nielsen et al. 1997). The structural homology between these “10 cysteine consensus” (10CC) 
regions most probably defines the core structural motif of the Vps10p domain (Petersen, 
Nielsen et al. 1997). Furthermore, the Vps10p domain of sortilin contains 6 additional cysteine 
residues, located more amino terminally when compared to the 140 amino acid core module 
(Figure 1.4).  
The intracellular, C-terminal domain of sortilin shows sequence stretches with homologies to 
mannose-6-phosophate (M6P) receptors. At the very C-terminal tail, a nine-residue sequence 
(HDDSDEDLL) is found which is also present in the extreme C-terminus of the M6P receptors 
(Petersen et al). This peptide contains a casein kinase II phosphorylation site and an adjacent 
dileucin motif, both mediators for the formation of clathrin-coated vesicles and further TGN 
sorting (Petersen, Nielsen et al. 1997). In addition, the cytoplasmic tail of sortilin contains two 
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more partly overlapping sorting signals. The sequence YSVL (consensus motif YXXZ) mediates 
rapid internalization of some membrane receptors, including proteins of the M6P receptor 
family. The other motif (FLVHRY), located in close proximity to the membrane-spanning domain 
and partly overlapping with the YSVL motif, constitutes another internalization/sorting signal. 
Again, this sequence stretch with the overall motif (F/Y)XXXX(F/Y) is also found in M6P 
receptors and in members of the LDLR family (Petersen, Nielsen et al. 1997).  
Sortilin is synthesized as an inactive precursor protein, which is converted to its active form by 
the proprotein convertase furin in late Golgi compartments. The furin cleavage site (R-4 - Xaa-3 - 
R/K-2 - R-1 - X+1) precedes the Vps10p domain at the protein’s amino terminus. Only after the 
maturation step, the receptor is able to bind its ligands, as is the case for the insulin receptor 
and LRP receptors (Ullrich, Gray et al. 1986). 
Once translocated to the plasma membrane, it has been proposed that sortilin serves as a 
scavenger receptor for lipoprotein lipase (LPL) and/or neurotensin. Following endocytosis, these 
proteins are degraded in lysosomal compartments of the cell (Mazella 2001).  
The numerous ligands already identified for this protein, its endocytic activity and the presence 
of structural motifs also found in other transmembrane receptors, provide evidence that sortilin 
presents a multifunctional protein involved in various cellular processes. 
 
1.4.3. LR11 / SorLA 
LR11 (LDLR related protein with 11 ligand binding domains, also termed SorLA), a highly 
conserved, 250 kDa type 1 receptor, belongs to the family of the LDLR related proteins 
(Jacobsen, Madsen et al. 2001). LR11 is a very complex seven-domain mosaic protein, which 
shows several interesting properties. The receptor shows > 80% sequence identity among 
mammals and birds, and its expression, in contrast to that of the LDLR, is not regulated by 
estrogen. Furthermore, LR11s are present in high amounts in the brain and have structural 
components which are not present in other members of the LDLR family. From its amino 
terminus towards its carboxy terminus, the extracellular or luminal part of the receptor is made 
up of a Vps10p domain which resembles that of sortilin, a cluster of five F/YWTD / beta 
propeller modules, an EGF-like module, a cluster of 11 LA repeats and a domain of six 
fibronectin type III repeats. The structural differences between sortilin and LR11 (SorLA) are 
shown in Figure 1.5.   
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Figure 1.5. Schematic representation of LR11  
(SorLA) and Sortilin. The extracellular domain of LR11 
is composed of a Vps10p domain (grey), five (F/Y)WTD 
/ beta propeller domains, an EGF-like module (open 
circle), 11 LA repeats (filled circles), and 6 fibronectin 
type III repeats (squares). In contrast, the Vps10p 
domain covers the whole extracellular part of sortilin. 
LR11, like sortilin, contains a furin cleavage site close to 
the amino terminus and preceding the Vps10p domain. 
The cleavage of the propeptide in the TGN converts the 
receptor into its active conformation (Figure adapted 
from (Jacobsen, Madsen et al. 2001)). 
 
 
 
 
 
 
LR11 harbours a single transmembrane domain and a cytoplasmic tail which contains the signal 
sequence (F/Y)XXXX(F/Y) and an acidic cluster (residues 2162-2170), characteristic for 
proteins with endocytic and / or sorting activity (Jacobsen, Madsen et al. 2001). Furthermore, 
Jacobsen et al (Jacobsen, Madsen et al. 2001) showed, using recombinantly expressed human 
LR11, that this receptor, like sortilin, is synthesized as an inactive proreceptor. After cleavage of 
the propeptide by furin in the TGN, the protein achieves its active conformation. The luminal 
Vps10p domain, as well as the domain containing LA-repeats, show effective ligand binding 
properties. Using surface plasmon resonance studies, (Jacobsen, Madsen et al. 2001) showed 
binding of RAP, LPL, neurotensin, and apoE to the luminal domains of human LR11. 
The site of highest LR11 expression was found to be the brain. This holds true for humans, 
rodents and also for avian species. In addition, to a smaller extent, mRNA of chicken LR11 
could be detected in the adrenal gland and testis (Morwald, Yamazaki et al. 1997). 
In addition to the role of LR11 as an endocytic receptor, the fact that a large amount of the 
protein localizes to perinuclear compartments led to the proposal that LR11 can also function as 
a sorting receptor (Jacobsen, Madsen et al. 2001).  
 
1.4.4. LRP1 
The low density lipoprotein receptor related protein 1 (LRP1) is one of the largest members of 
the LDLR family with an overall size of about 600 kDa. Its name is due to the fact that this 
unusually large membrane protein is composed exclusively of structural elements also present 
in the LDLR. In contrast to the seven ligand binding domains of the LDLR, LRP1 contains 31 
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LA-repeats clustered from the amino terminus into groups of 2, 8, 10, and 11 modules, 
respectively (Nimpf, Stifani et al. 1994). Furthermore, the receptor contains 22 EGF precursor 
homology domains (B1 and B2) and eight beta propeller structures carrying the YWTD motif 
(Figure 1.3). The receptor contains a single transmembrane segment. The intracellular stretch 
of about 100 amino acids contains two signals important for receptor endocytosis (Davis, van 
Driel et al. 1987). LRP1, like Sortilin and LR11, gets post-translationally modified by the 
protease furin, resulting in the generation of a 85 kDa membrane spanning protein and a 515 
kDa extracellular domain that remain non-covalently associated (Herz, Kowal et al. 1990).    
LRP1 is a multifunctional receptor involved in endocytic and signalling processes. To date it is 
known that LRP1 binds and subsequently endocytoses about 40 ligands, underlining the 
functional importance of this receptor. However, one of the most prominent ligands for LRP1 is 
alpha-2 macroglobulin (α-2M) (Strickland, Ashcom et al. 1990), a plasma protein that functions 
in inactivating proteinases present in the circulation. Therefore the receptor has also been 
termed LRP1/α-2M receptor. Mammalian LRP1 was shown to be the receptor which mediates 
the uptake and clearance of apoE-containing chylomicron remnants by the liver (Beisiegel, 
Weber et al. 1989). Furthermore, RAP was shown to be a ligand with chaperone function for 
LRP1.  
Essential signalling functions for LRP1 were described in the vessel wall, where it controls the 
proliferation of vascular smooth muscle cells, thereby protecting from atherosclerosis (Boucher, 
Gotthardt et al. 2003). LRP1 is also involved in signalling processes in the brain and in the lung 
(Boucher, Gotthardt et al. 2003).   
Chicken LRP1 was first described by Nimpf et al in 1994 (Nimpf and Schneider 1994), where an 
overall identity of 83% was observed between the protein sequence of chicken and its 
mammalian counterpart, with the intracellular domains being completely identical. Also the 
overall structures of human and chicken LRP1 are very similar. For instance, all cysteine 
residues present in the protein show perfect alignment between human and chicken. For the 
avian extracellular protein domain, Ca2+, α-2 macroglobulin, and vitellogenin were identified as 
binding partners (Nimpf, Stifani et al. 1994). Interestingly, the laying hen expresses two different 
α-2M’s. One is the classical, circulating α-2M with homology to the mammalian protein. The 
other one, termed ovostatin, also has high sequence similarity to mammalian and chicken α-2M 
(Nimpf, Stifani et al. 1994). In contrast, ovostatin is deposited into the egg white and is 
suggested to be the avian homologue to mammalian pregnancy zone proteins (Devriendt, Van 
den Berghe et al. 1991), which were also shown to bind LRP1 (Gliemann, Moestrup et al. 
1986). Pregnancy zone proteins are expressed at high levels in the human trophoblast, which 
forms the outer layer of the blastocyst (Gliemann, Moestrup et al. 1986). 
These findings suggest that LRP1 presents another important receptor involved in yolk 
deposition into the growing oocytes of egg laying species.   
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1.5. Aims of the Thesis 
Because apolipoprotein A-V (apoA-V) attracts more and more attention as a potent regulator of 
plasma triglyceride levels, the general aim of my thesis was to learn more about the biology of 
this apolipoprotein. In particular, I focused on the property of apoA-V to interact with cell surface 
receptors. Therefore, the elucidation of new binding partners of apoA-V in the chicken was a 
major objective of my work. Fortunately, it was possible to detect new interaction partners of 
ggapoA-V in the chicken embryonic yolk sac by ligand blot analysis. One of these proteins was 
identified as chicken cubilin, a protein involved in the endocytosis of various ligands. This 
interesting finding raised a number of questions and provided the basis for new ideas and 
experiments. 
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2. MATERIALS and METHODS 
2.1.Chemicals and Enzymes 
Chemicals used for the production of buffers, solutions, and media were obtained from: 
Amersham Biosciences, Amresco, Applichem, Bio-Rad, Calbiochem, Fluka, Gerbu, Merck, 
Pierce, Roche, Roth, Sigma Aldrich, Star Lab and Zymed. The following polymerases were 
used: DyNAzyme EXT DNA Polymerase from FINNZYMES, SUPERScript RNase H- Reverse 
Transcriptase II from Invitrogen, Pfu Ultra II Fusion HS DNA Polymerase from Stratagene and 
High Fidelity Polymerase from Fermentas. Other DNA-modifying enzymes used were T4-DNA 
ligase and Shrimp Alkaline Phosphatase (SAP) from Roche. All restriction enzymes were 
purchased from Roche and Fermentas Life Sciences.  
2.2. Bacterial Strains and Vector Systems 
 
Strain One Shot TOP10 Chemically Competent E. coli 
Genotype 
 
F-mcrA∆(mrr-hsdRMSmcrBC)φ80lacZ∆M15∆lacX74DeoRrecA1 
araD139∆(araleu)7697galUgalKrpsL(StrR)endA1nupG 
Reference/ 
Source 
Invitrogen 
 
      Table 2.1.  Bacterial strain used for transformations. 
 
Strain One Shot BL21 Star(DE3) Chemically Competent Cells 
Genotype 
 
F- ompT hsdSB (rB-mB-) gal dcm rne131 (DE3) 
Reference/ 
Source 
Invitrogen 
 
      Table 2.2. Bacterial strain used for recombinant protein expression. 
 
Vector pBluescript II SK(+/-) phagemid 
Size 2,961 basepair 
Genotype f1(+/-) origin, ColE1 origin, LacI, LacZ, MCS, Ampicillin 
Reference/ 
Source 
Stratagene 
       Table 2.3. Vector system used for cloning.     
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       Figure 2.1. Genetic map of pBluescript II SK (+). 
 
 
 
 
Vector pCR®2.1-TOPO® 
Size 3,931 basepairs 
Genotype LacZα fragment, M13 reverse priming site, MCS, T7 promoter/priming 
site, M13 forward priming site, f1 origin, kanamycin resistance, 
ampicillin resistance, pUC origin 
Reference / 
Source 
Invitrogen, TA cloning kit 
        Table 2.4. T/A cloning vector. 
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       Figure 2.2. Genetic map of T/A cloning vector pCR 2.1-TOPO. 
 
 
Vector pET25b(+) 
Size 3,931 basepairs 
Genotype  T7 promoter, T7 transcription start, pelB coding sequence, Multiple 
cloning sites (NcoI – XhoI), HSV Tag, His Tag, T7 terminator, lacI, 
pBR322 origin, bla, f1 origin  
Reference / 
Source 
Invitrogen, TA cloning kit 
       Table 2.5. pET-25b(+) expression vector. 
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       Figure 2.3. Genetic map of pET-25b(+) expression vector. 
 
 
2.3. Animals 
Derco brown laying hens (30-40 weeks old) were purchased from Heindl Co. (Vienna, Austria) 
and maintained on layer’s mash with free access to water and feed under a daily light period of 
16 hours. 
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2.4. Oligonucleotide Primers 
The designed oligonucleotides were synthesized by MWG-Biotech AG.  
 
pBluescript II SK(+/-) 
Name Sequence 
T3 5‘-AAT TAA CCC TCA CTA AAG GG-3‘ 
T7 5‘-TAA TAC GAC TCA CTA TAG GG-3‘ 
     Table 2.6. Specific primers used for sequencing PCR. 
 
 
T/A cloning vector 
Name Sequence 
M13fwd 5‘-GTA AAA CGA CGG CCA G-3‘ 
M13rev  5‘-CAG GAA ACA GCT ATG AC-3‘ 
     Table 2.7. Specific primers used for sequencing PCR. 
 
 
pET-25b(+) vector 
Name Sequence 
T7 promoter primer 5’-TAA TAC GAC TCA CTA TAG G-3’ 
T7 terminator 
primer 
5’-GCT AGT TAT TGC TCA GCG G-3’ 
     Table 2.8. Specific primers used for sequencing PCR. 
 
 
Primers used for cloning of the Cubilin fragment for antibody production 
Name Sequence 
Ab_fwd_NcoI 5’-AAC CAT GGT CTA TGA TGA ACA GCC  T-3’ 
Ab_rev_EcoRI 5’-TTG AAT TCG GTT TCC TCT GCA GAG T-3’ 
     Table 2.9. Chicken Cubilin sequence-specific primers.  
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2.5. Molecular Biological Methods: DNA 
2.5.1. cDNA Synthesis  
For the synthesis of cDNA, SuperScript II Rnase H- Reverse Transcriptase from Invitrogen was 
used. This enzyme synthesizes first strand cDNA and is able to generate cDNA up to 12.3 kb. 
Total RNA was isolated as described in 2.6.1. and the following components were mixed 
together in a nuclease free microcentrifuge tube: 
  1µl oligo (dT) primers 
  3-5µg total RNA 
  1µl 10mM dNTP mix (10mM each dATP, dGTP, dCTP and dTTP)  
  Sterile distilled water up to 12µl 
The mixture was heated to 65oC for 5min and afterwards quick chilled on ice. The contents of 
the tube was collected by brief centrifugation and the following components were added to the 
mixture: 
  4µl 5x First-Strand Buffer 
  2µl 0.1M DTT 
 
The contents of the tube was mixed gently and incubated at 42oC for 2min. 1µl of SuperScript II 
RT (200 units) was added to each tube and mixed gently by pipetting up and down. An 
incubation step of 50min at 42oC followed. To inactivate the reaction, the tubes were heated at 
70oC for 15min. 
The cDNA was now used as template for amplification in PCR. 
 
2.5.2. Polymerase Chain Reaction (PCR) 
To amplify specific DNA fragments from previously synthesized cDNA, the Thermocycler T3000 
from Biometra was used. PCRs were carried out with reaction volumes of 25 and 50µl. The 
polymerases used are listed in 2.1. Following components of a PCR reaction were mixed on ice 
in a nuclease free microcentrifuge tube: 
  50µl reaction volume 
  1µl cDNA 
  5µl 10x buffer (polymerase specific) 
  1µl forward + reverse primers (25pM / µl) 
  1µl dNTP mix (10mM) 
  1µl polymerase (Dynazyme or High Fidelity) 
  40µl ultrapure H2O 
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                         25µl reaction volume 
  0.5µl cDNA 
  2.5µl 10x buffer (polymerase specific) 
  0.5µl forward +reverse primers (25pM / µl) 
  0,5µl dNTP mix (10mM) 
  0.5µl polymerase (Pfu) 
  20µl ultrapure H2O 
 
An optimized PCR program  for the used primers and the length of the amplified fragment was 
chosen.  
 program 
Initial denaturation 10 min at 94°C 
Denaturation 30sec at 94°C 
Annealing 30sec at 55°C 
Extension 
 
40 cycles 
30sec at 72°C 
Last extension 10 min at 72°C 
 Table 2.10. Program used for PCR. 
All PCR products were analysed by agarose gel electrophoresis. 
 
2.5.3. DNA Gel Electrophoresis 
Separation of DNA fragments was performed by gel electrophoresis through 1 % (w/v) agarose 
gels with a constant voltage of 100 V for 30 min. DNA samples were mixed with 5x DNA loading 
buffer containing Bromophenol blue or Xylene Cyanol FF serving as front marker and glycerol to 
increase the density of the sample, ensuring that DNA can be evenly loaded into the sample 
well. 1x TAE was used as electrophoresis buffer. For size determination of DNA fragments, the 
1 Kb Plus DNA Ladder from Invitrogen was used. The agarose gel contained the fluorescent 
intercalating dye ethidium bromide to visualize the DNA fragments under ultraviolet light (366 
nm).  
 
50x TAE, pH 8.0 
2 M Tris/HCl 
1 M acetic acid 
0.1 M EDTA 
 
5x DNA loading buffer 
50 % Glycerin 
0.1 M EDTA 50x TAE Bromophenol blue or Xylen Cyanol FF 
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Ethidium bromide stock solution 
10 mg/ml in H2Odd 
 
StarPure AGAROSE from StarLab 
 
2.5.4. DNA Gel Extraction 
PCR products or restriction enzyme digested DNA fragments were extracted and purified from 
an agarose gel using the QIAquick Gel Extraction Kit Protocol from Quiagen. This protocol is 
used to extract and purify DNA of 70bp to 10kb from standard or low-melt agarose gels in TAE 
or TBE buffer. All centrifugation steps were carried out in a table centrifuge at the highest 
setting (13.000rpm). 
The desired DNA bands were excised from the gel using a sterile, sharp scalpel and transferred 
into a microcentrifuge tube. To one volume of gel, 3 volumes of buffer QG were added and the 
mixture was incubated for 10min at 50oC until the gel slice had completely dissolved. To help 
dissolve the gel, the samples were vortexed every 2-3min during the incubation. After the gel 
slice had completely dissolved, 1 gel volume of isopropanol was added and mixed. To bind 
DNA to a column, a QIAquick spin column was placed into a provided 2ml collection tube. The 
sample was loaded onto the column and centrifuged for 1min to bind DNA. The flow through 
was discarded and an additional centrifugation step was carried out with 0.5ml of buffer QG into 
the same collection tube. The flow through was discarded and the membrane was washed by 
adding 0.75ml PE, let the column stand for 5min and centrifugation for 1min After discarding the 
flow through, the QIAquick column was centrifuged for an additional 1min. The QIAquick column 
was placed into a clean 1.5ml microcentrifuge tube. To elute DNA, 30µl of elution buffer EB 
were applied directly to the centre of the membrane and let stand for 1min. Subsequently, the 
column was centrifuged for 1min and the purified DNA was used for further applications. 
 
2.5.5. Vector Dephosphorylation and Precipitation 
The vector pET-25b(+) was digested with the appropriate restriction enzymes. For ligation of 
DNA fragments into pET-25(b+) and pBluescript, these vectors were dephosphorylated (pET + 
pBluescript) and precipitated (pET-25b+). 
 
Dephosphorylation of pET-25b(+) and pBluescript 
20µl restriction reaction 
4µl 10x SAP buffer 
3µl SAP 
13µl ddH2O   
40µl total volume 
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The mixture was incubated 15min at 37oC, dephosphorylation was inactivated for 20min at 
65oC. 
Precipitation of pET-25b(+) 
40µl dephosph. reaction 
27µl 1M NaAc 
54µl Isopropanol 
14µl ddH2O  
 
The vector was vortexed and precipitated for at least 30min at –20oC. The vector was 
centrifuged for 30min at 4oC and 13.000rpm and the pellet was washed with 1ml 70% Ethanol. 
After an additional centrifugation step for 10min at 4oC and 13.000rpm, the supernatant was 
discarded and the vector pellet was dried for 5min at 37oC. 
 
2.5.6. DNA Ligation 
Ligation of a vector with the DNA of interest was carried out using the TOPO vector from the 
TOPO TA Cloning Kit (Invitrogen) or pET-25b(+) and pBluescript vector systems. Desired DNA 
fragments were extracted and purified from agarose gels as described in 2.5.4. Vectors and the 
DNA of interest were cut with the appropriate restriction enzymes. The following components 
were mixed on ice in sterile microcentrifuge tubes: 
 
Ligation using the TOPO vector system 
4µl fresh PCR product 
1µl Salt Solution 
1µl TOPO vector 
 
The ligation was mixed gently and incubated for 5min at RT. Tubes were placed on ice before 
proceeding to One Shot Chemical Transformation. 
 
Ligation using pET-25(b+) and pBluescript vector systems 
Dry pET-25b(+) vector pellet / 1µl pBluescript 
17µl pure PCR product 
2µl 10x Ligation buffer 
1µl T4 DNA Ligase 
 
Components were mixed well and the ligation reaction was incubated o.n. at 18oC.  
MATERIALS and METHODS   
   
34 
2.5.7. Transformation of competent E. coli 
One aliquot (50µl/tube) of One Shot TOP10 Chemically Competent E. coli or One Shot BL21 
Star(DE3) Chemically Competent Cells was defrosted for 5min on ice. 2 to 10µl of the ligation 
reaction were directly pipetted into the vial of competent cells and mixed by tapping gently. The 
reaction was incubated on ice for 30min. The cells were heatshocked for 30sec at 42°C and 
chilled on ice for 2min. 250µl of provided S.O.C. medium were added and the cells were 
incubated for 1hr at 37°C by shaking for regenerati on. 50 and 150µl of the transformation 
mixture were plated onto LB-Amp, LB-Amp/X-Gal or LB-Kan/X-Gal plates and incubated o. n. at 
37°C. White colonies were checked for containing th e correct plasmid by mini-preparation of the 
plasmid DNA, followed by restriction enzyme digestion.  
 
2.5.8. Mini Preparation of Plasmid DNA 
Plasmid DNA was isolated using the Fast Plasmid Mini kit from Eppendorf. The kit provides a 
fast, non-organic method for isolating high purity plasmid DNA from 1.5 to 3ml of E.coli  
bacterial cultures. The Fast Plasmid Mini technology uses a single solution for cell 
resuspension, lysis and DNA trapping. 
The Complete Lysis Solution is stored at 4oC for all applications. All centrifugation steps were 
performed in a table centrifuge at RT and 13.000rpm.  
1.5ml of E.coli o.n. culture transformed with a specific plasmid was transferred in a provided 2ml 
microcentrifuge tube and pelleted by centrifugation for 1min. The supernatant was decanted 
and 400µl of ice cold Complete Lysis Solution were added. The cells were resuspended by 
constant vortexing for 30sec at the highest setting. Afterwards the lysate was incubated for 3min 
at RT. The lysate was transferred to a Spin Column Assembly and centrifuged for 1min. 400µl 
Diluted Wash Buffer were added to the Spin Column and the column was again centrifuged for 
1min. The filtrate was discarded and the Spin Column was placed back into the waste tube. 
Another centrifugation step was done to dry the Spin Column. The Column was transferred into 
a provided Collection Tube and 50µl of Elution Buffer were added directly to the center of the 
Spin Column membrane. To elute plasmid DNA, the Column was centrifuged for 1min. The 
eluted DNA was immediately used for downstream applications or stored at –20oC until usage. 
 
2.5.9. Midi Preparation of Plasmid DNA 
For the midi-preparation of plasmid DNA the QIAfilter Plasmid Midi Kit from QIAGEN® was 
used. All centrifugation steps were carried out in Sorvall GSA and HB-6 rotors. 25ml of LB 
medium containing the appropriate antibiotic was inoculated with a single colony or with 100µl 
of mini - o.n. culture and incubated o. n. at 37°C by vigorous shaking. The bacterial cells were 
harvested by centrifugation at 6000x g for 15min at 4oC. The supernatant was discarded and 
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the cell pellet was resuspended in 4ml of buffer P1 until no cell clumps remained. After adding 
4ml of buffer P2 and mixing thoroughly by vigorously inverting the sealed tube 4-6 times, the 
lysate was incubated at RT for 5min. During the incubation periode, the QIAfilter Cartridge was 
prepared and 4ml chilled buffer P3 were added to the lysate. After mixing by inverting 4-6 times, 
the lysate was poured into the barrel of the QIAfilter Cartridge. The mixture was incubated at RT 
for 10min. During the incubation periode, the QIAGEN-tip 100 was equilibrated by applying 4ml 
of buffer QBT, and the column was allowed to empty by gravity flow. The cap was removed from 
the QIAfilter Cartridge outlet nozzle and the plunger was gently inserted into the QIAfilter Midi 
Cartridge. Afterwards, the lysate was filtered into the previously equilibrated QIAGEN-tip. The 
lysate was allowed to enter the resin by gravity flow and the QIAGEN tip was washed 
subsequently with 2x 10ml of buffer QC. The DNA could be eluted with 5ml of buffer QF into a 
sterile 15ml Falcon tube. 3.5ml of isopropanol were added to precipitate the eluted DNA. After 
mixing, the sample was immediately centrifuged at 15.000x g for 30min at 4oC. The supernatant 
was carefully decanted and the DNA pellet was washed with 2ml of room temperature 70% 
ethanol. After an additional centrifugation step at 15.000x g for 10min the supernatant was 
carefully decanted. The DNA pellet was air-dried for 5-10min at RT and finally the DNA was 
redissolved in a suitable amount of ddH2O. DNA concentration was determined using the Nano 
Drop from PeqLab with a wavelength of 260nm. 
The purified plasmid DNA was immediately used for downstream applications or stored at -20oC 
until usage. 
Buffer P1 (resuspension buffer) 
50 mM Tris-Cl, pH 8.0 
10 mM EDTA 
100 µg/ml RNase A 
 
Buffer P2 (lysis buffer) 
200 mM NaOH 
1 % SDS (w/v) 
 
Buffer P3 (neutralization buffer) 
3.0 M potassium acetate pH 5.5 
 
Buffer QBT (equilibration buffer) 
750 mM NaCl 
50 mM MOPS, pH 7.0 
15 % isopropanol (v/v) 
0.15 % Triton® X-100 (v/v) 
 
Buffer QC (wash buffer) 
1 M NaCl 
50 mM MOPS, pH 7.0 
15 % isopropanol (v/v) 
 
Buffer QF (elution buffer) 
1.25 M Nacl 
50 mM Tris-Cl, pH 8.5 
15 % isopropanol (v/v) 
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2.5.10. Restriction Enzyme (RE) Digestion 
The following components were mixed and incubated for 90min at 37oC in a sterile 
microcentrifuge tube: 
 
  5µl Mini Prep / 5µg Midi Prep 
  2µl specific RE buffer 
  0.5µl RE 
  ddH2O up to a final volume of 20µl 
 
The appropriate restriction buffer was chosen in agreement with the recommendations of the 
manufacturer. The degree of digestion was checked by agarose gel electrophoresis. 
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2.6. Molecular Biological Methods: RNA 
2.6.1. Isolation of total RNA 
Total RNA was isolated from tissues using the NucleoSpin RNA II Kit from Genxpress (Machery 
Nagel). About 30 to 40mg of freshly or frozen tissue were weighed into a sterile Eppendorf tube 
containing 350µl buffer RA1 and 3.5µl ß-Mercaptoethanol. Tissues were homogenized using a 
Potter and filtered through a NucleoSpin Filter Column (violet ring) to reduce viscosity. The 
mixture was applied onto the column and centrifuged for 1min at 11.000x g in a 2ml Collection 
tube. The NucleoSpin Filter Column was discarded and 350µl 70% Ethanol were added to the 
lysate by pipetting up and down. For each preparation, one NucleoSpin RNA II Column (light 
blue ring) was placed into a new 2ml Collection tube. The lysate was pipetted up and down 2-3 
times and loaded to the column. The sample was centrifuged for 30sec at 11.000x g and the 
Column was placed into a new collection tube. For desalting the membrane, 350µl MDB 
(Membrane Desalting Buffer) were loaded and centrifuged for 1min at 11.000x g to dry the 
membrane. To remove contaminating DNA, a DNase reaction mixture was prepared in a sterile 
microcentrifuge tube. For each isolation, 10µl rDNase was added to 90µl Reaction buffer for 
rDNase and mixed by flicking the tube. This mixture was added directly to the center of the 
silica membrane of the column and incubated at RT for 15min. To wash and dry the silica 
membrane, 200µl buffer RA2 were added to the NucleoSpin RNA II column and centrifuged for 
30sec at 11.000x g. The column was now transferred to a new collection tube. A second wash 
step was done with 600µl RA3 followed by a centrifugation step for 30sec at 11.000x g. The last 
washing step was performed by adding 250µl RA3 to the NuceloSpin RNA II column. The 
column was centrifuged for additional 2min at 11.000x g to dry the membrane completely. 
Afterwards the column was placed into a nuclease-free Collection tube. For elution of highly 
pure RNA, 60µl of RNase free Water (supplied) was added directly to the center of the 
membrane and centrifuged for 1min at 11.000x g. RNA concentration was measured with the 
NanoDrop from PeqLab and the RNA´s were stored at –80oC until usage. 
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2.7. Molecular Biological Methods: Protein 
2.7.1. Preparation of Triton X-100 Total Protein Extracts 
Freshly or frozen obtained chicken tissues were placed in ice-cold homogenization buffer (4 
ml/g wet weight) and homogenized with an Ultra-Turrax T25 homogenizer 3 times for 20 
seconds each. The homogenates were centrifuged for 10 min at 620x g and 4oC. The 
supernatant was transferred to a fresh tube and 1/20 of 20% Triton X-100 was added. The 
mixture was than incubated for 30 minutes at 4oC and finally centrifuged at 60.000 rpm for 1 
hour at 4oC. The supernatant was pooled and the protein concentration was determined by the 
method of Bradford using the BioRad protein assay (BIORAD). 
Homogenization Buffer: 
20 mM Hepes pH 7.4 
300 mMSucrose 
150 mM NaCl 
Proteinase inhibitor cocktail tablettes (ROCHE) 
 
2.7.2. Preparation of Triton X-100 Membrane Protein Extracts 
Buffer A (4 ml/g net weight) was added to the tissue samples, followed by homogenization using 
an Ultra-Turrax T25 homogenizer, 3 times for 20 seconds each. If necessary, homogenization 
was extended until the homogenization was complete. The samples were centrifuged at 2000x 
g for 10 minutes at 4oC in a SS34 rotor and the supernatant was poured over four layers of 
cheesecloth into a fresh beaker on ice. The filtrate was centrifuged using an Ultra-centrifuge at 
50.000 rpm for one hour at 4oC. The supernatant was discarded and the pellets were washed 
as follows: They were resuspended in 3ml buffer A by aspirating through an 18gge needle and 
then flushed through a 22gge needle. The suspensions were combined in a fresh beaker on ice 
and aliquots were centrifuged at 50.000 rpm for 1 hour at 4oC. The supernatant was discarded 
and the pellets were resuspended in 5ml buffer B, flushing again through an 18gge needle and 
then through a 22gge needle. Afterwards 4% of the total volume of 4M NaCl was added and the 
samples were sonicated for 30 seconds at setting 6. Finally, 1/10 of 10% Triton X-100 was 
added to the samples and centrifuged for 1 hour at 4oC and 50.000 rpm. The supernatant was 
aliquoted and stored at -80oC until usage. Protein concentration was determined using the 
method of Bradford. 
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Buffer A 
20 mM Tris/HCl 
1 mM CaCl2 
150 mM NaCl 
Proteinaseinhibitor 
 
Buffer B 
250mM Tris/Maleat, pH 6 
2mM CaCl2 
Proteinaseinhibitor 
 
2.7.3. SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Extracted and recombinant proteins were separated on 10%, 12% and 4.5-18% gradient gels 
with a thickness of 1 mm using the BioRad Mini gel system.   
Components 
(1gel) 
Stacking 
gel 4% 
Separating 
gel 6% 
Separating 
gel 10% 
Separating 
gel 12% 
Gradient 
gel 18% 
Gradient 
gel 4,5% 
H2Odd 1525µl 2650µl 2025µl 1675µl 435µl 1920µl 
1.5 M Tris-HCl 
pH 8.8 
- 1250µl 1250µl 1250µl 810µl 810µl 
0.5 M Tris-HCl 
pH 6.8 
625µl - - - - - 
30% 
polyacrylamide 
325µl 1000µl 1650µl 2325µl 1980µl 495µl 
10% SDS 25µl 50µl 50µl 50µl 31,5µl 32,25µl 
10% APS 12.5µl 50µl 25µl 25µl 25µl 25µl 
TEMED 2.5µl 4µl 2.5µl 5µl 5µl 5µl 
 Table 2.11. Ingredients of a protein gel. 
 
The components of the separating gel were mixed and poured into the previously cleaned gel 
unit and overlayed with a small quantity of isopropanol. The gel was allowed to polymerize for 
about 15min. The components of the stacking gel were combined and poured onto the 
separating gel after complete removal of the isopropanol. The combs were inserted and the 
stacking gel was allowed to polymerize for at least 15min. After removal of the combs, the slots 
were rinsed with ddH2O and the gel was put into the buffer chamber filled with electrophoresis 
buffer. The protein samples were mixed with Laemmli buffer (reducing or non-reducing; as a 
reducing agent, Dithiothreitol (DTT) was added up to a final concentration of 25mM) and 
incubated for 5min at 95oC (only samples under reducing conditions). The gel was run at 80V 
until the samples reached the separating gel and then shifted to a constant voltage of 180V until 
the Bromphenol Blue front reached the bottom of the gel. As a protein marker, Unstained 
Precision Plus Protein Standard (Bio Rad) served as size markers. For every protein gel, 8µl 
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marker was applied. The gels were used for Coomassie blue and Silver Stainings or for 
Western and Ligand Blot analysis as described below. 
 
30% Polyacrylamide 
29.2% acrylamide 
0.8% N,N´-methylenebisacrylamide 
 
4x Laemmli buffer  
8ml 78% glycerine 
6ml 20% SDS 
0.4ml 1M Tris-HCl pH 7.4 - 7.5 
ddH2O to a final volume of 20ml  
+25mM Dithiothreitol (DTT) for reducing conditions 
 
1x Electrophoresis buffer 
25 mM Tris 
0.192 M Glycine 
1% SDS 
 
2.7.4. Western Blot Analysis 
Semi Dry Blotting 
Transfer of proteins from SDS-gels to nitrocellulose membranes (HybondTM-C Extra for 
optimized protein transfer, from Amersham Biosciences) was performed in a BioRad semi-dry 
blotting unit. The blot was prepared as followed: three Whatman papers soaked in 1x transfer 
buffer were applied to the blotting unit, followed by the nitrocellulose membrane, the gel and 
finally three more soaked Whatman papers. To avoid air bubbles, which decrease the quality of 
protein transfer, a falcon tube was rolled over the blot. The blot was covered with the lid of the 
blotting unit. Blotting was performed for 90min at 200mA for one gel, at 400mA for two gels and 
so on. To check the transfer efficiency, the membrane was stained with Ponceau S. Blotted 
proteins and the standards were visualized by destaining with ddH2O. The bands in the protein 
standard lane were marked with a pencil. 
 
Detection 
Enhanced Chemiluminescence (ECL) was used to visualize proteins on immunoblots. ECL is 
based on enzyme-catalyzed production of light where horse raddish peroxidase conjugated to 
the secondary antibody catalyzes the oxidation of luminol in the presence of H2O2. The 
membrane was blocked for 1 hr at room temperature (RT) with 5% non-fat dry milk in 1x TBST. 
After removing the blocking solution, the primary antibody diluted in 5% milk in 1x TBST was 
added. Dilutions of the antibody were dependent on its affinity. The blot was incubated for at 
least 1 hr at RT or overnight (o.n.) at 4oC with gentle agitation. Then the membrane was washed 
3 times each for 10min with 1x TBST, followed by the addition of an appropriate amount of 
secondary, HRP conjugated antibody in 5% milk 1x TBST. After 1 hr of incubation at RT with 
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gentle agitaion, the solution was discarded and the membrane was washed another 3 times 
with 1x TBST for 10min each. Finally, the membrane was incubated in a 1:1 mixture of ECL 
solution I and II (Pierce) for three minutes and put into an exposure cassette. Films (Kodak) 
were exposed in the dark room, depending on the intensity of the signal and background. 
 
1x Transferbuffer 
25mM Tris/HCl 
192mM glycine 
 
1xPBS 
137mM NaCl 
0.27mM KCl 
10mM Na2HPO4 
1.7mM KH2PO4 
 
1x TBST 
25mM Tris/HCl pH 7.4 
140mM NaCl 
2.5mM KCl 
0.1% Tween 20 
 
Ponceau S 
0.2% Ponceau S 
1x PBS 
3% Trichloracetic acid 
 
2.7.5. Ligand Blot Analysis 
Blotting of proteins to the Nitrocellulose membrane and subsequent blocking of the membrane 
was performed according to Western Blots. The blocking buffer used in ligand blot experiments 
was 1x TBST + 2mM CaCl2 + 5% non-fat dry milk.  
After blocking of the nitrocellulose membrane for at least 1 hr at RT, a specific ligand was added 
to the incubation solution to allow for binding to proteins immobilized on the membrane in the 
presence of CaCl2. Ligand incubation was performed o.n. at 4oC under gentle agitation. After 
removal of the ligand solution, the membrane was washed 3 times for 20min with 1x TBST + 
2mM CaCl2. After washing, a ligand-specific antibody was diluted in 1x TBST + 2mM CaCl2  + 
5% non fat dry milk and applied to the membrane. The blot was incubated for at least 1 hr at RT 
with gentle agitation. Subsequently the membrane was washed three times each for 10min with 
1x TBST + 2mM CaCl2, followed by the addition of an appropriate amount of secondary, HRP 
conjugated antibody in 1x TBST + 2mM CaCl2 + 5% milk. After 1 hr of incubation at RT under 
gentle agitation, the solution was discarded and the membrane was washed another three times 
with 1x TBST + 2mM CaCl2 for 10min each. Finally, the membrane was incubated in a 1:1 
mixture of ECL solution I and II (Pierce) for three minutes and put into an exposure cassette. 
Films (Kodak) were exposed in the dark room, depending on the intensity of the signal and 
background. 
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2.7.6. Reverse Ligand Blot 
Transfer of proteins from SDS-gels to nitrocellulose membranes was performed as described 
above (2.7.4. Western Blot Analysis). Ligands, normally used for forward blotting were 
transferred to the nitrocellulose membrane and the specific protein bands were cut from the 
membrane. Single membrane pieces were incubated o.n. at 4oC in Eppendorf-tubes under 
gentle agitation with protein extracts containing potential binding partners for the protein blotted 
to the nitrocellulose membrane. After removal of the protein extract, membrane pieces were 
washed 3 times for 5min with 1x TBST + 2mM CaCl2 on an Eppendorf thermomixer 5436 at 
maximum speed at RT. Afterwards, each membrane piece was transferred into a separate, 
fresh tube. Elution of proteins bound to the nitrocellulose membrane was achieved by the 
addition of 100µl of 0,1M Citric acid, pH 2.5 to the membrane piece and shaking of the mixture 
for 2min on the thermomixer at maximum speed. To concentrate the amount of eluted proteins, 
membrane pieces treated under the same conditions were pooled. Elution was accomplished 
with an appropriate amount of Citric acid. The eluate was now loaded to SDS-PAA gels and 
subsequently used for Coomassie blue – and/or Silver staining for the detection of eluted 
proteins. 
 
2.7.7. Protein detection using Coomassie Blue staining 
After gel electrophoresis, the gel was incubated for 1 hr in Coomassie brilliant blue solution. 
After removal of the Coomassie solution, the gel was incubated in Destain solution for 1-2 hours 
until protein bands became visible.  
 
Coomassie Blue solution     
10% Acetic acid 
25% Isopropanol 
0.287g Coomassie Brilliant Blue R250 in ddH2O. 
 
Destain 
10% Acetic acid 
30% Methanol in ddH2O 
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2.7.8. Silver Stain 
Silver staining of proteins in gels was performed using the SilverSNAP Stain Kit II from Pierce. 
All steps for the silver staining of proteins in Polyacrylamide Gels were performed in a single 
clean staining tray with constant gentle shaking. Fixing, Ethanol and Stop solutions were 
prepared in advance. Other solutions were prepared immediately before use.   
After gel electrophoresis, the gel was washed 2 times for 5min with ddH2O. For fixation, the gel 
was incubated in fixing solution 2 times for 15min consisting of 30% ethanol and 10% acetic 
acid in ddH2O. After fixation, the gel was washed with two changes of 10% ethanol in ddH2O 
and another two times for 5min each in ddH2O. For sensitizing, the gel was incubated for 
exactly 1min in Sensitizer Working Solution by mixing 1 part SilverSNAP Sensitizer with 500 
parts ddH2O. Then the gel was washed with two changes of ddH2O for 1min each. For the 
staining reaction, Stain Working Solution was prepared by mixing 1 part SilverSNAP Enhancer 
with 50 parts SilverSNAP Stain. The gel was incubated in Staining Solution for 30min and 
subsequently washed with two changes of ddH2O for 20sec each. The Developer Working 
Solution was prepared by mixing 1 part SilverSNAP Enhancer with 50 parts Silver SNAP 
Developer and the gel was incubated in Developer Working Solution until protein bands appear 
(2-3 minutes). When the desired band intensity was reached, the Developer Working Solution 
was replaced with prepared Stop Solution (5% acetic acid in ddH2O). After a brief washing step, 
the Stop Solution was replaced and incubated for additional 10min. For storage, the gels were 
soaked in 5% Glycerin in ddH2O for 2-3 hours or o.n., and afterwards dried using the vacuum 
gel drier at 65oC.  
 
Blum Silver Staining for Mass Spectroscopy    
For the delivery of protein samples for Mass Spectroscopy, the Silver Stain protocol of Blum 
(Blum, H., Beier, H., and Gross, H.J. 1987 Electrophoresis 8, 93-99) was used. 
The gel was fixed in 40% Ethanol / 10% Acetic acid in ddH2O for 1 hr. Afterwards the gel was 
washed 2 times for 20min in 30% Ethanol / ddH2O and 1 time for 20min in ddH2O. Sensitzing 
was done for 1min in Sensitizer Solution. Now the gel was washed with three changes of ddH2O 
for 20 seconds each. Silver staining was performed in Sliver Solution for 20min at 4oC followed 
by washing with three changes of ddH2O. Development was carried out in Developer Solution 
until protein bands appeared (3-5min). The gel was washed with ddH2O for 20sec and the 
staining reaction was stopped by incubating the gel in Stop Solution for 5min. After washing 3 
times for 10min with ddH2O, the gels were stored in ddH2O containing 1% acetic acid. Protein 
bands were now cut from the gel in a cell culture lamina and sent to the MFPL Mass 
Spectroscopy facility. 
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Sensitizer Solution 
0.02% Sodioum thiosulfate in ddH2O   
 
Silver Solution 
0.1% Silver nitrate in ddH2O 
 
Developer Solution 
3% Sodium carbonate 
0.05% Formaldehyde in ddH2O 
 
Stop Solution 
5% Acetic acid in ddH2O 
 
2.7.9. Expression and Purification of Recombinant Proteins  
A small amount of an E.coli glycerol stock, transformed with the pET-25b(+) expresssion vector 
containing the gene of interest cloned into the multiple cloning site of the vector, was inoculated 
into 6ml of LB-Amp medium and incubated o.n. at 37oC under vigorous shaking. The o.n. 
culture was inoculated into 500ml of LB-Amp medium in a sterile flask and incubated at 37oC on 
the shaker (145rpm). Cells were grown to an optical density (OD 600) of 0.6 and protein 
expression was induced by adding Isopropyl ß-D-1- thiogalactopyranoside (IPTG) to a final 
volume of 1mM. Protein expression was performed for 3 hours at 37oC on the shaker (145rpm). 
Afterwards the cells were harvested by centrifugation for 15min at 4oC and 3500 rpm in a 
Sorvall centrifuge using a GS3 rotor. The cell pellet was resuspended in 10ml of Lysis buffer 
with proteinase inhibitor (ROCHE). The cell suspension was sonicated 8 times for 30sec at 4oC, 
and the lysed cells were centrifuged for 15min at 4000rpm and 4oC using a Heraeus table 
centrifuge. The supernatant was poured into a fresh 50ml Falcon tube and filled up to a final 
volume of 50ml with Lysis buffer / proteinase inhibitor (ROCHE). To this mixture, 1ml of Ni-NTA 
Sepharose beads was added and rotated o.n. at 4oC. Beads were harvested by centrifugation 
for 5min at 3500rpm and 4oC and the supernatant was removed. To remove contaminations 
from the beads they were washed 4 times with 25ml of Wash buffer. After each washing step, 
the beads were harvested by centrifugation for 5min at 3500rpm and 4oC. Proteins (expressed 
with an C-terminal His-Tag) bound to the Ni-NTA beads were eluted 2 times in 1ml of Lysis 
buffer / proteinase inhibitor (ROCHE) by rotating the beads for 15min at 4oC at the highest 
setting. The beads were again harvested by centrifugation and the supernatant was collected. 
To remove Imidazol from the collected samples, the solution was dialyzed for 1 hr against 1x 
TBS + 125mM Imidazol, 1 hr against 1x TBS + 60mM Imidazol and o.n. against 1x TBS at 4oC 
using the SnakeSkin Pleated Dialysis Tubing (7,000 MWCO) from Pierce. After dialysis, the 
protein concentration was determined using the method of Bradford. Pure protein samples were 
stored at -80oC until usage.  
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Lysis buffer 
50mM Tris/HCl pH 8.0 
500mM NaCl 
1% Trition X-100 
10% Glycerol 
20mM Imidazol 
 
Wash buffer 
50mM Tris/HCl pH 8.0 
500mM NaCl 
0,15% Tween 
10% Glycerol 
1% Triton 
30mM Imidazol 
 
Elution buffer 
50mM Tris/HCl pH8.0 
500mM NaCl 
250mM Imidazol 
 
2.7.10. Co-Immunoprecipitation 
Co-immunoprecipitation was carried out to precipitate a protein complex of two proteins.  
A protein extract was diluted 1:10 in 1x TBST/2mM CaCl2 and mixed with a recombinant protein 
source, proposed to be a binding partner for proteins present in the extract, for 2 hours on a 
rotator at 4oC under gentle agitation. Following this pre-incubation, an antiserum, specific for the 
recombinant protein, was added in appropriate amounts.  
Samples were incubated for at least 1 hr at 4oC on a rotator under gentle agitation. After this 
incubation period, the Protein A Sepharose beads (usually 50-70µl wet volume) were added to 
the mixtures. Samples were incubated overnight at 4oC under gentle agitation as mentioned 
above. The next day, the samples were centrifuged for 3min at 2000 rpm and 4oC. The 
supernatant was discarded and the beads were washed three times with 1ml 1x TBST + 2mM 
CaCl2 + proteinase inhibitor (ROCHE). In between the washing steps, the beads were 
centrifuged for 3min at 2000 rpm and 4oC to remove the supernatant. After the final washing-
step, the supernatant was discarded and an appropriate amount of 4x Laemmli buffer + 25mM 
DTT were added to the protein A beads. Afterwards, samples were incubated 5min at 95oC to 
separate the proteins from the beads. Samples were centrifuged and the supernatant was 
applied to SDS-PAGE. The immunoprecipitated proteins could now be analyzed (Coomassie 
gel, Silver stain, or Western blot).   
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2.7.11. Affinity Chromatography 
Coupling a ligand to cyanogen bromide (CnBr) activated Sepharose 4B (GE Healthcare): 
All buffers used were filtered using a glass filter funnel from Millipore (Filter: Type HA / 0.45µm) 
to remove undissolved material. 3mg of ligand for coupling to the beads was dialyzed o.n. 
against coupling buffer for the removal of chemicals which would impair the coupling reaction. 
1g of CNBr Sepharose beads were swollen in 1mM HCl by rotating the beads at RT for 30min. 
To remove additives, the beads were washed with 100ml of 1mM HCl on a glass filter funnel. 
The beads were activated by adding and immediate sucking of 20ml coupling buffer. The 
activated beads were transferred into a 50ml Falcon tube already containing the ligand solution 
(~20ml) + proteinase inhibitor (ROCHE). For the binding of the ligand to the beads, the protein-
Sepharose mixture was rotated for 2 hours at RT.  Using the glass filter funnel, the liquid was 
sucked and the beads were washed with 150ml of coupling buffer. To block remaining binding 
sites on the Sepharose beads, and to avoid unspecific binding, the beads were incubated with 
30ml of 1M Ethanolamin / HCl, pH 8.3 and rotated for 2 hours at RT. The Ethanolamin was 
removed and the beads were washed with 60ml of buffer A and B alternately according to the 
following scheme: 
 2 times buffer A, 2 times buffer B 
 4 times buffer A and buffer B alternately 
Finally, the beads were washed with Storage buffer + proteinase inhibitor and resuspended in 
the same buffer in a 50ml Falcon tube. The coupled beads were stored at 4oC in Storage buffer 
until usage. 
 
Coupling buffer pH 8.5 
0.1M NaHCO3 
0.5M NaCl 
 
Buffer A pH 8.0 
0.1M Boric acid 
1M NaCl 
 
Buffer B pH 4.0 
0.1M NaAc 
1M NaCl 
  
Storage buffer pH 7.4 
25mM Tris/HCl 
0.01% EDTA 
0.02% NaN3 
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Equilibration and packaging of the column 
Packing and equilibration of the column as well as affinity chromatography (AC) were done at 
4oC. All buffers and materials were cooled to 4oC before use. The column used was an Econo-
Pac Column from Bio-Rad with a total volume of ~12ml and an inner diameter of 0,8cm.  
The column was first equilibrated in 100ml AC buffer. Afterwards the diluted protein extract was 
loaded onto the column and the extract was allowed to circulate for 2 hours through the column. 
Before loading the extract onto the column and after the incubation period, samples were taken 
from the protein extract for analysis. The column was washed with 400ml AC buffer for the 
removal of unspecific proteins present in the column. After the washing step, an aliquot of 
beads was removed.  
 
Affinity chromatography buffer (AC buffer) pH 7.4   
20mM Tris /HCl 
0.2% NP40 (Detergent) 
2mM CaCl2 
150mM NaCl 
 
Elution  
The elution step of the AC column was done with buffers in consecutive steps. All elution 
fractions were collected in Eppendorf tubes for further analysis on Coomassie and Silver stain 
gels. 
Elution was carried out 2 times with 1ml of 25mM EDTA + proteinase inhibitor and afterwards 2 
times with 1ml of 4M NaCl + proteinase inhibitor. The column was washed with 20ml of AC 
buffer whereas the first four ml of this washing step were also collected in tubes. 
 
Regeneration of the ligand-coupled beads 
The column was washed with 20ml of buffer A and buffer B two times alternately. 
 
Storage of the column  
The beads were stored in Storage buffer + proteinase inhibitor at 4oC. 
 
2.7.12. Antibody Generation 
Antiserum against chicken Cubilin was raised against a 96-amino acid fragment located in the 
very N-terminal region of the protein, which represents the only structurally unique motif of the 
protein. This fragment was cloned, expressed, and purified according to the methods described 
above. 
For the first injection, 300µg of antigen-mix was mixed with GEBRO complete adjuvant and 
injected intradermally to an adult New Zealand White rabbit. Boosters were performed with the 
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antigen in complete GEBRO adjuvant 3 and 6 weeks after the first injection with 300µg of 
antigen mix. Blood samples were taken after 8 weeks, incubated at RT for 1 hr and afterwards 
stored o.n. to let coagulation proceed. After stirring the coagulated blood samples with a metal 
stirrer, the samples were centrifuged at 4000 rpm for 15 min. The supernatant representing the 
antiserum was aliquoted and stored at –20°C. The ob tained serum was tested by Western blot 
analyses. Preimmune serum from the same rabbit served as control.  
 
2.7.13. Utilized Antibodies and Antisera 
 
                Protein                              Specific antibody                                    Dilution 
ggApoA-V Rabbit anti-ggApoA-V antiserum   (1:2000) 
hApoA-V Rabbit anti-hApoA-V antiserum  (1:1000) 
hApoA-V-His Mouse anti-His antibody  (1:1000) 
ggCubilin Rabbit anti-ggCubilin antiserum  (1:2000) 
ggLRP 380 Rabbit anti-LRP 380 antibody  (1:1000) 
ggLRP2 Rabbit anti-LRP2 antibody  (1:1000) 
ggLRP1 Rabbit anti-LRP1 antibody  (1:1000) 
ggLR8 Rabbit anti-LR8 antibody  (conc. 10µg/µl) 
ggLR8B Rabbit anti-LR8B antibody  (1:1000) 
ggLR11 Rabbit anti-LR11 antibody  (1:1000) 
GST-RAP Mouse anti-GST antibody  (1:2000) 
Rabbit IgG Goat anti-rabbit IgG  (1:50 000) 
Mouse IgG Goat anti-mouse IgG  (1:1500) 
Table 2.12. Used antibodies and antisera. 
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3. RESULTS 
Generally, the aim of my diploma thesis was to expand our work on the biology of apoA-V in our 
model organism, the chicken. In more detail, I focused on the interesting property of apoA-V to 
bind and interact with certain cell surface receptors in its lipid-associated and lipid-free form, 
which was shown by in vitro studies using SPR and ligand blotting (Dichlberger, Cogburn et al. 
2007; Nilsson, Christensen et al. 2008). Many studies in the past have shown that apoA-V 
circulates in the plasma in a lipid-bound form on the surface of Chylomicrons, VLDL, and HDL 
lipoproteins. There, apoA-V mediates the clearance of these particles from the circulation by 
various mechanisms. However, the physiology of lipoprotein-associated apoA-V is not 
completely understood. In addition, evidence exists that apoA-V is also present in a lipid-free 
form in the plasma. To gain better insights into the functional properties of apoA-V as a 
modulator of triglyceride levels, we wanted to identify new binding partners of ggapoA-V.  
 
 
 
3.1. Search for New Interaction Partners of ggapoA-V 
 
As indicated in the Introduction, several studies reported the high affinity of apoA-V to bind to 
and interact with certain cell surface receptors. Human apoA-V was shown to bind to the LDLR 
related proteins LRP and LR11, and to a protein belonging to the family of Vps10p-domain 
receptors termed sortilin (Nilsson, Lookene et al. 2007; Nilsson, Christensen et al. 2008). 
Furthermore, in our lab it was shown that ggapoA-V binds to the chicken VLDLR homologue 
LR8 (Dichlberger, Cogburn et al. 2007), located on the surface of the chicken oocyte. This 
interaction was studied by using ligand blot analysis, a well established method used in our lab. 
Because this receptor-ligand interaction can be demonstrated very reproducibly with the applied 
ligand blot methodology, the binding of ggapoA-V to LR8 served as a consistent positive control 
during my experiments (Figure 3.1).   
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Figure 3.1. Chicken apoA-V binds to the major oocyte receptor LR8. A laying hen (LH) small white 
follicle (SWF) membrane protein extract was prepared, and 100µg extract per lane were subjected to 
non-reducing, 4.5%-12% gradient gel SDS-PAGE and blotted to nitrocellulose membrane. After blocking 
of unspecific binding sites with blocking buffer, ggapoA-V (150µg crude bacterial protein extract) was 
added as a ligand (lane 1). After extensive washing, the bound ggapoA-V protein was detected using α-
ggapoA-V antiserum. To lane 2, a specific α-LR8 antibody was applied to verify the presence of the 
receptor. As a secondary antibody, an HRP-conjugated α-rabbit antibody was used. Visualization was 
performed using ECL.       
 
 
 
To gain more insights into the biology of ggapoA-V concerning its receptor-binding ability, ligand 
blot analyses were expanded using other chicken tissues as a potential source for new 
interaction partners of ggapoA-V. The chicken brain, chicken adrenals, and the embryonic yolk 
sac, tissues known to utilize and/or metabolize lipids and lipoproteins, were selected for binding 
studies by ligand blots. No interaction partners of ggapoA-V could be identified when adrenal 
protein extracts were used as a source for possible receptors. Furthermore, ligand blotting was 
applied to chicken brain protein extracts. Generally, the brain is an interesting tissue for 
interaction studies of apoA-V with proteins expressed there. Two receptors, LR11 and sortilin, 
for which it is known that their major site of expression is the brain, were shown to be binding 
partners for hapoA-V (Nilsson, Lookene et al. 2007; Nilsson, Christensen et al. 2008). 
Furthermore, LR8B, a member of the LDLR family with eight ligand-binding domains is known to 
be specifically expressed in the brain (Stockinger, Hengstschlager-Ottnad et al. 1998). 
Nevertheless, ligand blot analysis did not unambiguously reveal an interaction partner of 
ggapoA-V in the chicken brain (Figure 3.2.); possibly, binding to LR11 and LR8B could be seen 
(lanes 1,3).   
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Figure 3.2. Ligand blot analysis with ggapoA-V on chicken laying hen brain extracts 
under non-reducing conditions. Brain total extracts (200µg/lane) were subjected to SDS-
PAGE on 4.5 – 12% gradient gels and afterwards blotted to a nitrocellulose membrane. After 
blocking, the membrane strips were incubated with ggapoA-V crude protein extracts (lanes 1-3). 
After extensive washing, bound apoA-V was detected using ggapoA-V antibody (lanes 1-4).  As 
a control for the quality of the brain protein extract, receptors present in the chicken brain  
(LR11, LR8B) were detected using specific antibodies (lanes 5 and 6). Bound primary 
antibodies were detected using an HRP-conjugated α-rabbit antibody. Visualization of the blot 
was done using ECL. 
     
 
Several ligand blots with crude ggapoA-V as well as with purified ggapoA-V as ligand could not 
clearly confirm the binding of the protein to LR11. Nevertheless, faint bands can be seen for 
ggapoA-V interacting with a protein at 250 kDa (lanes 1 and 3), which is also the size of LR11 
(lane 6). Another band, representing ggapoA-V bound to the nitrocellulose membrane, appears 
at ~80 kDa (lane 2), co-migrating with the second immunoreactive protein recognized by the α-
LR11 antibody (lane 6). The high background seen in lanes 1-3 likely was the result of long 
exposure times.  
Because no clearly identifiable interaction partner of ggapoA-V could be observed in the brain, 
the yolk sac (YS), an extraembryonic structure essential for chicken embryonic development, 
was tested. Chicken yolk sac, isolated at day 10 of chicken embryonic development, was used 
for further ligand blot experiments. A yolk sac membrane protein extract was prepared to avoid 
contaminations with yolk and other components that are in close contact with the two cell layers, 
which form this sac-like structure.  
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When ggapoA-V was used as a ligand on yolk sac membrane extracts, two interaction partners 
were observed (Figure 3.3, lane 1). One ggapoA-V binding protein had a size of approximately 
110 kDa, the other one migrated with a molecular mass of more than 250 kDa. When no ligand 
was added to the membrane, none of these proteins were detected (lane 2). This confirms that 
the presence of apoA-V is essential to detect these proteins. To exclude the possibility that the 
larger binding partner of ggapoA-V presents chicken LRP2, which is known to be present in the 
yolk sac, lane 3 was probed with an α-LRP2 antibody. A clear difference in the molecular mass 
of the ggapoA-V binding partner (large band in lane 2) and LRP2 (lane 3) was observed. 
 
 
 
Figure 3.3. Ligand blot analysis with ggapoA-V on chicken yolk sac membrane extracts. 150µg of 
freshly prepared chicken yolk sac membrane extract per lane was subjected to 4.5-12% gradient gel 
SDS-PAGE under non-reducing conditions and subsequently blotted to nitrocellulose membrane. The 
membrane was cut into single strips, and 150µg ggapoA-V crude protein extract was added to the 
membrane representing the ligand (lane 1). After extensive washing, the bound ligand was detected 
with an α-ggapoA-V antibody. No ligand was added to lane 2, and lane 3 was probed with an α-LRP2 
antibody. HRP-conjugated goat α-rabbit antibody was used as secondary antibody, and visualization of 
the blot was performed using ECL.     
 
 
The interaction partners of ggapoA-V in the yolk sac could be consistently detected in several 
different ligand blots exclusively under non-reducing conditions (no binding can be detected 
under reducing conditions, data not shown). The bands visualized on the ligand blot (Figure 3.6, 
left panel) represents high affinity binding of ggapoA-V to protein(s) present in the chicken yolk 
sac.  
Having discovered new binding proteins of ggapoA-V in the yolk sac, the question came up of 
how to identify and characterize these proteins. In the first attempts, I performed Co-
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immunoprecipitations (Co-IP) using protein A-Sepharose beads. For the binding of ggapoA-V to 
its receptors, the ligand was incubated with diluted yolk sac membrane extract for 2 hours. 
Then, α-ggapoA-V antiserum was added to the mixture to capture any complexes of apoA-V 
with interacting proteins. The mixture was rotated over night in the presence of Protein A –
beads. After washing, the bound proteins were eluted from the beads and analyzed on a 
Coomassie-stained gel (Figure 3.4, right panel).    
 
 
                                             
Figure 3.4. Left panel: Ligand blot under non-reducing conditions showing ggapoA-V binding to 
proteins present in the chicken yolk sac. Yolk sac protein extract was subjected to 4.5-12% SDS-
PAGE and subsequently blotted to nitrocellulose membrane. As a ligand, 5µg purified ggapoA-V were 
added to the membrane strip. Bound apoA-V was detected using α-ggapoA-V antiserum. HRP-
conjugated goat α-rabbit antibody was used as secondary antibody, and visualization of the blot was 
performed using ECL. Right panel: Coomassie stain following Co-IP. Proteins bound to the protein 
A-Sepharose beads were eluted with reducing Laemmli buffer and subjected to gradient-gel SDS-
PAGE. In lane A, the specific α-ggapoA-V antiserum was used, whereas lane B shows the Co-
immunoprecipitation with preimmune serum.   
 
 
The performed Co-IP’s (Figure 3.4, right panel) did not identify any binding partners of ggapoA-
V. The strong band observed in both lanes (< 50 kDa) represents the rabbit IgG heavy chain 
(IgG dissociates in the presence of reducing agents into its heavy and light chains), which 
bound to the protein A-Sepharose with its conserved domain (Fc – domain). In lane A (which 
shows the Co-IP with the α-ggapoA-V antibody), but not in lane B (Co-IP with preimmune 
serum), a faint band underneath the IgG heavy chain can be seen. This band represents most 
probably the precipitated ggapoA-V. Nevertheless, no other proteins could be precipitated. 
Rather than using a more sensitive method for the detection of co-IPed proteins (such as silver 
staining the gel), another method, reverse ligand blotting, was used for the identification of the 
RESULTS   
   
54 
ggapoA-V binding proteins.  Here, recombinant ggapoA-V was blotted onto the nitrocellulose 
membrane. After staining of the proteins with PonceauS, the specific region of the membrane, 
representing the ggapoA-V protein fraction (molecular mass of 40kDa), was cut out from the 
membrane. These membrane pieces were incubated with diluted yolk sac membrane extract to 
let the binding reaction proceed. After washing, proteins which bound to the membrane-
immobilized ggpoA-V could be eluted with citric acid (see “Materials and Methods” and legend 
to Fig. 3.5). The eluted fraction was subjected to SDS-PAGE and subsequently silver staining 
was performed for the detection of the apoA-V binding proteins (Figure 3.5). 
 
 
 
 
Figure 3.5. Silver stain gel following reverse ligand blot. 150µg recombinantly expressed ggapoA-V 
crude protein extract was subjected to SDS-PAGE under non-reducing conditions and then transferred 
to a nitrocellulose membrane by semi-dry blotting. The membrane piece containing the ggapoA-V 
protein band was cut out and incubated with diluted yolk sac membrane extract. After end-over-end 
rotation over night, the membrane pieces were washed. Binding partners of ggapoA-V were then eluted 
from the nitrocellulose membrane pieces with ~ 300µl 0.1M citric acid, pH 2.5. The elution was 
subjected to 4.5-12% gradient gel SDS-PAGE and proteins were detected using the silver stain method 
by Blum, a special method optimized for subsequent Mass Spectroscopy.   
 
 
By reverse ligand blotting, it was possible to elute a protein, whose molecular mass resembled 
that of the larger interaction partner of ggapoA-V observed by forward ligand blotting (Figure 
3.4, left panel). Other silver stains also revealed the second, smaller ggapoA-V binding partner 
(~110 kDa, figure3.3, lane 1), although in the reverse-ligand blotting experiments the amount of 
this protein was much lower. 
For the identification of the binding partner of ggapoA-V (Figure 3.5, lane 2), the protein band 
was cut from the gel under sterile conditions and sent to the VBC Mass Spectroscopy facility. 
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The analysis of the protein via Mass Spectroscopy was successful and identified a huge protein, 
comprising 3728 amino acids, predicted to be the chicken homologue of mammalian cubilin. In 
figure 3.6, the identified peptides which span the whole sequence are highlighted in red. 
As cubilin was the only chicken protein thus identified, the result is quite significant. Additionally, 
detailed reports in the literature revealing mammalian cubilin as a lipoprotein receptor underline 
the importance of this result even more. Cubilin, a peripheral membrane protein known to be 
involved in endocytic processes, also matched perfectly to the observed function of apoA-V in 
terms of binding to various cell surface receptors.    
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     1 MVEEEEEEDE DEEEGSDEEE KGLLSFDVFG QPPLNQRTNP SDDSIPGDLG  
    51 QQPIEQLKVR SSNVQCPDPT LCQAHIPQDH KLNQGMVAAA QATFSVDIFD  
   101 DLFCIVALLL LAGLSCESNH YEKKRQKRNI YDEQPRLSSE QGNLVFHAGS  
   151 SKNIEFRTGP LGKIKLNEED LAEMFSQMRE NKAEIQELKK ASGVSQNVSH  
   201 QVSMLASKVT SLDMKLQSLE QTLQRKACSS NPCENSGTCV NSLDGFFCLC  
   251 PSNWRGLRCS EDINECQIYA GTALGCQNGA TCVNTPGSYS CSCTPETYGP  
   301 RCASKFDDCQ GGSQTLCEHG TCVDAERDTP NKPKYHCICD TGWMSPPGSP  
   351 ACSADIDECS LPNPPCSQNP RVQCHNTLGS YSCDPCPTGW QGNGYSCQDI  
   401 DECESDNGGC STAPMVQCIN TIGSFRCGVC PPGYEGDGQT CTQVDSCSIN  
   451 NGGCHPSATC TSTPGLMPFC SCSPGYTGSG YGPNGCSPLT DICQLQNPCA  
   501 NGQCLAVTSG YFCLCNAGWT GSNCTENIDE CISNPCQNGG SCTDGVNGYT  
   551 CECTSAWTGP QCQTAQQACG GYLSGSRGTF SYPNNPSSQH YDTGVSCAWV  
   601 IQTASNKILH ITFPFFHLEA STDCNSDFLQ IHDGASASMH MLGKYCGSNP  
   651 PAELFSSHNS LYFWFHSNHA VTAGGFTVQW DSRDPECGGE LTATYGSISS  
   701 PGYPGNYPVN RDCFWTISTN PGLLITFAFG TLSLEHHENC SYDYLEIRDG  
   751 LLSQDSVLGK YCSTGSPPPL QTTGPYAWIH FHSDDEVTDK GFHIVYTTSA  
   801 ADPTCGGNYT DSEGVITSPF WPNSFINSQQ CIYIIRQPED EKIHLNFTHL  
   851 ELESHAGCSL NYIEVRDGDS EMSSLITRFC HSTVISPITS TSNSLWIKFK  
   901 SDASVQRASF RAVYQVACGG SLSGEGTIHS PYFPRMSSQP KTCEWIISQS  
   951 VSKVVILNFI DFDIRNTTTC DSDYVEVRDG NNTESPLLGK YCGTAVPSRV  
  1001 QSTRNNLYIK FRASSLTNLG FRAQYWPLDT VCGESLTGSE GTITSPGFPD  
  1051 VYPHGINCIW TINVQPGYLI RLTFTSFNLP FHSSCRMDYL EIYDNSTMQK  
  1101 LGRYCGRSIP PSLTSGGNVM MLYFVTDRSI SSEGFSANYI SLDASKVCSH  
  1151 NYNTETGVLT SPNYPNNYPV QTECIYTITV GINRQIVLRF TNFTLEGNLR  
  1201 CTEDYIEIRD GGYETSPYLG KYCGSGLPPV IISHGNKLWI KFVSDIFGTR  
  1251 KGFSAEWDGT SAGCGGTLTT SSGIFMSPNY PMPYYHSSEC YWLLRGSRGT  
  1301 PFEIQFEQFH LEYHPNCNFD YLAVYDGNSS NAKQLGKFCG NQIPQFINSS  
  1351 GDSVYIKLRT DSSVHGGGFL AKYKQVCHEV LTVNRSYGVL ESLNYPNNYP  
  1401 LGEHCRWTIQ TTKGNTLSYS FTAFDVEDGS NCDRDYLKLY DGPNVQSNLI  
  1451 GTFCGQSLPL AGNSTGTSLH VEFYSDGLQA RSGFQMLWHT NGCGGELSGP  
  1501 SGSFHSPGYP NRYPSNRECI WYIQTTPGSS IQLTIQEFDV EYHPNCNYDV  
  1551 LEVFGGPDFL SPRLAQLCIS RSAQNPLLLS TTGNSAVVRF KTDEAVTGKG  
  1601 FSASWQENLH GCGGIFQANS GEIHSPNYPE PYSNNTDCSW LIQVDYSHRV  
  1651 LLNFTDFDIE DHRLCNYDNV TVFDGPSNEA PLLRVLCGTQ HPSPITSSRN  
  1701 QMYVRLRSDR TFQHRGFSAR FSEACGSFIE SDSVGAAISS PLYPAKYPNN  
  1751 QNCSWIIQAQ EPFNHVTLSF TDFDIENNRQ NCTTDFVEIL DGNNYDAPLQ  
  1801 GRYCGTNMPH PITSFGNALV VNFISNNNIT TRGFHATYAA SSSSCGGTFH  
  1851 MDRGAFNSPG YPESYPLNTE CVWTILSSPG NRLQLSFTAF QVESSSGCTK  
  1901 DYLEIREGNA TGTLAGKFCG DSLPSNYTST VGHILWVKFV SDSSGTDVGF  
  1951 RATFSHLYGN DIVGNRGQIA SPQWPRSYPH NSNYQWRIST NASQVIHGRI  
  2001 LEMDIENHYR CYYDKLKVYD GPTIHSRPIA TYCGADPASF ASSGSTLTIQ  
  2051 FQSDSSVTGR GFLLEWYAME PSAPTRTIAR GACGGTVTSE ETPSFLYSPG  
  2101 WPLNYRNFAD CVWLIRAPGS TVEFNILALD IESHSSCYYD RLTIQDGDNG  
  2151 LSPLLATICG REPPGPVRST GETMFIRFVS DGSVTGAGFN ASYHKSCGGY  
  2201 LHADRGVITS PSYPQEYTPN LNCSWHVLVT SGYIITVHFE QPFQVKSEDA  
  2251 SCNSGDYVEL KNGLDASAPP LVSGRGNGRF CGSSPISTMY TTDNQLFVHF  
  2301 ISDSRNEGQG FKLKYEAKSL ACGGNIYISD FNPSGYTSSP NYPNNYPSHA  
  2351 DCVWTITAPN GHAVELQFED QFYIEPSPNC TSSYLELRNG ADSSAPVLAK  
  2401 LCGSLLPGSQ RSSGAVMYLR FRSDSSSTHV GFNAKYSIAP CGGTVAGRSG  
  2451 VIESVGYPDL HYPDNLLCEW FLQGPRGHYL TITLEDLDIQ NTSECASDFV  
  2501 EIREYNASGN LLGRYCGNTL PDAVDTSDSF AYVKFVADGS INARGFRLRF  
  2551 DSSTEECGGD FSAPVGMFTS PNYPNRYPHN RVCEWRITVE EGRRVILTIN  
  2601 DMRTEEHWRC SSDYVAVYNG LRQNSPRLVK LCGEVNPGTE VKSSGNTMKV  
  2651 VLVTDMTHAT RGFSVSYTSN EDSVCGGTLM GYTGGNFSSP GYDGVKNYTS  
  2701 KLNCEWTIEN PSHYNSSIYI SFEDFHLEHH QDCQYDYLEL RIGDADGELI  
  2751 ARLCGQAAPS VPLVIAAPQV WIHFVSDENT EDKGFLGRYI FEACGGIQSG  
  2801 ERGFISSPNY PEPYGNLNHC SWLLEAPEGE TITLNFTAFH VENHSLCKWD  
  2851 SVTILNGGSP GSPVIGRYCG NTSPGIIQSG SNKLLVIFNS DRSIQGGGFY  
  2901 ATWTAESLGC GGIIHSDSGM IKSPHWPQNF PMNTRCTWTI ITHESKHLEM  
  2951 IFHNNFQIPH SDGSCQSSFV KVWQGNHEEE EALLATGCGT SAPDPVIAPN  
  3001 NIVTTVFQSR DAPGRGFSAS FISRCGINFT SPAGRIVSPN YPSQYDNNLN  
  3051 CSYIIDRGPQ SLVILEFETF HLEAPALLSR ICLYDGVSIF RGTRVTPHPV  
  3101 ITLCGSEVPE PISVFGPMLL NFYTDSHIAG FGFQARYRTI ACGGTFSGSV  
  3151 GIISSPAHSV LDYHNNMNCS YHITVGSGKA VVLKFNTFQL ELSPSCYKDS  
  3201 VAVYDGSDTH APLLGKFCGS ELPPNMKSSS NQLFLVFNTD FSGSDRGWKA  
  3251 SFRETLGPQD GCGGYLTYSA YSFGSPVSNV SGRYERNLDC VWVITAPVNK  
  3301 LINLTFTSFV LEAHVAQTCQ YDYVKLYDGG NENANLVGTF CGSIVPAPFL  
  3351 STSNSLTLKF VTDNSVQREG FSATYTTVDR LCGGTYNATS TSLTATSPNF  
  3401 PSEYPPFTLC TWVIDAPPQQ QVKVVVETFH LHPSQDCSQN YLQLQDLPMH  
  3451 SQGSTHRFCG NETFPVPEFY SHDRTAIVTF KSDEYRINNG VRFTYQATGC  
  3501 SREYNQPFGY LKSPGWPGRH PNNMDCSIVL KAPLNHTISL FFHAFSLEDS  
  3551 IQCSHDFLEV RNGSNMQSPL LGRFCGNTVP SPIFPQSHVV FLRFKSDVSG  
  3601 AHDGYEITWT SSSSGCGGTL YGSTGTFASP RFPATYWNNT HCEWVITVPK  
  3651 GRIVTVNFDF ISIDDPGDCS SNYLILYNGP DTSYPQAGPY CGMDTNIAPF  
  3701 TATSHQVYVK FHAEYVTLPS GFRLSWTS 
 
Figure 3.6. Identification of the ggapoA-V binding protein via Mass Spectroscopy. The protein 
which was eluted from the reverse ligand blot (arrow in Fig. 3.7) was cut out from the silver stain gel 
and analyzed by the VBC Mass Spectroscopy facility. The peptides which could be identified are 
highlighted in red. These peptides were confirmed by database search to match perfectly to a chicken 
protein similar to mammalian cubilin.  
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Having identified cubilin as a potential ggapoA-V binding partner, it was now important to verify 
the presence of this protein in the chicken yolk sac. Because of the high degree of sequence 
conservation observed in the cubilin protein (Figure 3.7), we first tested whether an antibody 
directed against mouse or rat cubilin would also recognize chicken cubilin. 
 
 
 
Figure 3.7. Sequence alignment of the amino terminus of chicken (Gg), human (Hs) and mouse 
(Mm) cubilin using ClustalW (MacVector). Identities are shown in grey, revealing a relatively high 
sequence conservation across species. Interestingly, the cubilin prepeptide which precedes the furin-
cleavage site (underlined in green) in the chicken protein is by far the longest of the three. 
 
 
Thus, we searched for an antibody that would recognize the chicken protein. Finally, we 
obtained an aliquot of antiserum from a research group in Texas, which had generated an 
antibody against mouse cubilin (Crider-Pirkle, Billingsley et al. 2002). Unfortunately, this 
antibody showed no cross reactivity with chicken cubilin, as shown in figure 3.8. This α-mouse 
cubilin antibody recognizes mouse and rat cubilin in kidney protein extracts (Figure 3.8, lanes 1, 
3), but not chicken cubilin in the yolk sac (Figure 3.8, lane 5). Nevertheless, mouse and rat 
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cubilin (Figure 3.8, lanes 1,3) shows the same size as chicken cubilin, as determined by ligand 
blot analysis of chicken yolk sac extract (Figure 3.8, lane 4). Moreover, ggapoA-V shows 
binding to a protein present in the mouse kidney (Figure 3.8, lane 2). This protein migrates 
exactly at the same size as the second interaction partner detected in the chicken yolk sac 
(Figure 3.8, lane 4, see Fig. 3.4). In contrast, ggapoA-V shows no binding to mouse cubilin 
(Figure 3.8, lane 2). 
 
 
 
Figure 3.8. Western/Ligand blot analysis under non-reducing conditions for the detection 
of chicken cubilin in the yolk sac. The indicated protein extracts were subjected to gradient-
gel SDS-PAGE and blotted to nitrocellulose membrane. Cubilin was detected using an α-mouse 
cubilin antibody (lanes 1, 3, 5). GgapoA-V (5µg pure, recombinant protein) was used as a ligand 
in lanes 2 and 3 and detected using an α-ggapoA-V antiserum. HRP-conjugated α-rabbit 
antibody was used for the detection of the primary antibodies.   
 
 
Because it was not possible to detect chicken cubilin with the α-mouse cubilin antibody, I 
started with the generation of an α-chicken cubilin antibody, an important tool for further 
experiments. Because cubilin consists of repetitive structural domains also present in several 
other proteins, we decided to raise the antibody against the very N-terminal domain, a 
sequence stretch comprising 96 amino acids, which follows the furin cleavage site (Figure 3.7). 
This part of the protein is unique for cubilin, therefore presenting a good target for antibody 
formation (Fig. 3.9).  
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Figure 3.9. Cubilin peptide for antibody production. The protein region chosen for antibody 
generation is highlighted in red. This 96 amino acid stretch represents the only unique part of cubilin. 
The furin cleavage site is shown in blue, the prepeptide in green. The cysteine residues (yellow) mark 
the beginnig of the EGF domains which immediately follow the selected antigen region.  
 
    
The DNA stretch corresponding to the cubilin antibody peptide, i.e., the predicted cDNA 
sequence for chicken cubilin in the PubMed Nucleotide database, is shown in figure 3.10. The 
sequence corresponding to the furin cleavage site (bold, black, underlined) and the primers 
used (blue and red, underlined) are shown.    
 
 
 
Figure 3.10. Start of the Chicken cubilin cDNA containing the fragment which encodes the 
antibody peptide. Light red = transcriptional start codon; underlined and bold bases = furin cleavage 
site; blue, underlined = forward primer with an additional NcoI restriction enzyme cleavage site (5’-AAC 
CAT GGT CTA TGA TGA ACA GCC  T-3’);  dark red, underlined = reverse primer with an additional 
EcoRI restriction enzyme cleavage site (5’-TTG AAT TCG GTT TCC TCT GCA GAG T-3’). Restriction 
enzyme cleavage sites are essential for the cloning of the fragment into the vector systems used. 
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For the amplification of the DNA fragment which encodes the antibody peptide, PCR was 
performed from yolk sac and kidney cDNAs following preparation of total RNAs from these 
tissues. Primers were used as described above, and the PCR reaction product was analyzed on 
a 2% agarose gel containing ethidium bromide (Figure 3.11). Bands were obtained in cDNAs of 
both tissues. It appears that cubilin may be more abundant in chicken kidney (Figure 3.11, lane 
1) than in yolk sac (Figure 3.11, lane 2).  
 
 
 
 
Figure 3.11. RT-PCR for amplification of the cubilin DNA fragment chosen for antibody 
generation. PCR products were analyzed on a 2% agarose gel containing ethidium bromide. Lane 1, 
the PCR product amplified from LH kidney cDNA; lane 2, yolk sac cDNA. PCR products were cut out 
from the gel and used for subsequent cloning reactions.  
 
 
After cloning of the fragment into the pBluescript vector and confirmation of the sequence 
(obtained from the VBC sequencing facility), the DNA fragment encoding the antibody peptide 
was cloned into the expression vector pET-25b(+) using the restriction enzymes NcoI and 
EcoRI. The DNA fragment was again verified by DNA sequencing, and the vector containing the 
cubilin insert was transformed into the E.coli expression strain BL21. The recombinant chicken 
cubilin antibody fragment was expressed with a C-terminal 6x-His tag provided by the pET-
25b(+) vector system. The induction of protein expression is shown in figure 3.12. 
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Figure 3.12. Induction of the expression of the His-tagged cubilin antibody peptide in E.coli 
strain BL21. The cubilin antibody peptide was expressed as a fusion protein containing a C-terminal 
His-tag. Bacteria were grown to an OD of 0.6 and protein expression was induced by addition of 1mM 
IPTG. 0 = before induction of protein expression; 1 = one hour after the induction of protein expression; 
2 = after 2 hours of expression; 3 = after three hours of expression. At every time point, samples were 
removed and subsequently subjected to SDS-PAGE. Proteins were detected using a Coomassie Blue 
stain. 
 
 
I was fortunate that the protein was expressed efficiently in high amounts. Therefore, the protein 
was purified using Ni-NTA Agarose, which binds proteins via their His-tag, and the purification 
results were analyzed by Western blotting using an α-His antibody (Figure 3.13). 
 
 
 
Figure 3.13. Western blot analysis for the detection of the recombinantly expressed and purified 
cubilin antibody peptide with α-His antibodies. After protein expression, the crude bacterial protein 
extract was incubated with Ni-NTA Agarose for the purification of the protein via its His-tag. Lane 1 
shows the proteins which did not bind to the Ni-NTA beads; lane 2 shows the wash fraction (beads 
were extensively washed);  lanes 4 and 5 show  the eluted protein detected with α-His antibodies. 
 
The soluble, purified protein was used for antibody generation. 300µg protein was injected into 
a New Zealand White rabbit and booster injections with the same amount of protein were 
administered 3 and 6 weeks after the primary immunization. After 8 weeks, the specificity of the 
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rabbit antiserum was tested by Western blot analysis on LH kidney and yolk sac protein extracts 
(Figure 3.14.). The antiserum, designated α-ggCubilin antiserum, clearly recognizes a protein of 
the expected size in kidney and yolk sac protein extracts, in agreement with the presence of 
cubilin in these tissues. No immunoreactive band was observed when probing the same blots 
with preimmune serum, confirming the specificity of the antiserum. Interestingly, the Western 
blot under reducing conditions in figure 3.14 shows, that the proteins in the kidney and yolk sac 
recognized by the α-ggCubilin antiserum seem to be slightly different in size. 
 
 
Figure 3.14. Western blot analysis of chicken cubilin in kidney and yolk sac under reducing 
conditions. Protein extracts were subjected to SDS-PAGE and blotted to a nitrocellulose membrane. 
For the detection of Cubilin in these extracts, lanes 1, 2, 4, and 5 were incubated  with the α-ggCubilin 
antiserum (dilution 1:2000). Preimmune serum was used as a negative control (Lanes 3, 6). As 
secondary antibody, HRP-conjugated goat α-rabbit antibody was used and visualization was performed 
using ECL.  
 
 
However, Western blots under non-reducing conditions show that the immunoreactive band 
recognized by the α-ggCubilin antiserum in the yolk sac appears diffuse (Figure 3.15, lanes 3, 
4), whereas in the kidney the band was much narrower (Figure 3.15, lanes 1, 2). One 
explanation for this different migration pattern of the immunoreactive protein could be different 
extents of glycosylation of cubilin in kidney versus yolk sac. Furthermore, only in the yolk sac, 
the antibody recognizes a band at about 140 kDa under non-reducing conditions (Figure 3.15, 
lanes 3, 4).  
Thus, to obtain supportive evidence that the α-ggCubilin antiserum recognizes chicken cubilin, 
the α-mCubilin antiserum was used as a positive control (Figure 3.15, lane 5, 6). Chicken and 
rat cubilin show almost the same size, indicating that the protein recognized by the α-ggCubilin 
antiserum indeed represents its target (compare also with Fig. 3.8).        
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Figure 3.15. Western blot analysis of cubilin in chicken and rat tissues under non-reducing 
conditions.  Protein extracts were subjected to SDS-PAGE and blotted to nitrocellulose membrane. For 
the detection of chicken cubilin, the nitrocellulose membrane strips were probed with the α-ggCubilin 
antiserum (lanes 1, 2, 3, 4). For the detection of rat cubilin, the α-mCubilin antiserum was used (lanes 5, 
6). As secondary antibody, HRP-conjugated goat α-rabbit antibody was used, and visualization was 
performed using ECL.  
 
 
To further confirm that ggapoA-V interacts with chicken cubilin, ligand blots were performed, 
and in adjacent lanes, cubilin was detected with the α-ggCubilin antiserum (Figure 3.16, lanes 
1, 2, 3). The same size of the band detected with the specific antiserum (lanes 1, 3) and with 
the ligand ggapoA-V (lane 2, faint band) confirms that ggapoA-V binds to chicken cubilin. The 
ligand interaction was again solely observed under non-reducing conditions. Importantly, it 
needs to be pointed out that ligand blotting for the analysis of cubilin has not been previously 
reported.   
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Figure 3.16. Western/Ligand blot for the confirmation of the ggapoA-V – cubilin interaction. 
Chicken yolk sac and kidney protein extracts were subjected to non-reducing SDS-PAGE and 
subsequently blotted to nitrocellulose membrane. Chicken cubilin was detected in both tissues using α-
ggCubilin antiserum (lanes 1, 3). As a ligand, ggapoA-V was added to the membrane strip in lane 2, 
and after washing, bound ggapoA-V was detected using α-ggapoA-V antiserum. HRP-conjugated goat 
α-rabbit antibody was used as secondary antibody, and visualization was performed using ECL. 
 
 
 
To identify new interaction partners of ggapoA-V in the yolk sac, and to further confirm the 
ggapoA-V – cubilin interaction, I performed affinity chromatography. To this end, I recombinantly 
expressed and purified 3mg of full-length ggapoA-V cloned into a pET25b(+) vector system, 
kindly provided by Andrea Dichlberger in the lab. The ggapoA-V was coupled to CNBr-activated 
Sepharose 4B beads (Figure 3.17, panel A), and affinity chromatography was performed using 
freshly prepared yolk sac membrane extract. The protein extract was allowed to circulate 2 
hours through the affinity column containing the ggapoA-V-coupled beads. Following washing of 
the beads with approximately 350ml of wash-buffer, bound proteins were eluted from the 
column. The pooled eluted fractions were dialysed, lyophilized and dissolved in a small amount 
of ultrapure water. The sample was analyzed by silver stain for the detection of the eluted 
proteins (Figure 3.17, B). Interestingly, 2 proteins could be eluted from the affinity column, likely 
representing binding partners of ggapoA-V (lanes 5, 7). The protein in lane 7 has the size 
observed for chicken cubilin, in agreement with the above-presented evidence for a ggapoA-V – 
cubilin interaction. The protein in lane 5, with an apparent molecular mass of about 200 kDa 
may represent a hitherto unidentified ggapoA-V binding partner in the embryonic yolk sac. 
Whether this protein corresponds to the second immunoreactive band recognized by the α-
ggCubilin antibody in the yolk sac seen under non-reducing conditions (Figure 3.16, lane 1) 
awaits analysis by mass spectroscopy.   
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Figure 3.17. Affinity chromatography. 3mg of ggapoA-V were coupled to CNBr-activated Sepharose 
4B beads, and the coupling efficiency was confirmed by elution of the bound proteins from the beads 
and Coomassie blue stain (Figure 3.16, A). The ggapoA-V coupled beads were incubated with freshly 
prepared yolk sac extract isolated from chicken embryos at day 10 of embryonic development. After 
extensively washing, the ggapoA-V binding proteins were eluted. Fractions of 1ml were collected, 
dialysed and concentrated by lyophilization. After dissolving in ~120µl ultrapure water, each fraction 
was subjected to silver staining following SDS-PAGE (B).  Lane 1, last wash fraction before elution; 
lanes 2 and 3, consecutive 25mM EDTA elutions; lanes 4 and 5, consecutive 4M NaCl elutions; lanes 6 
and 7, consecutive wash fractions after elution with 4M NaCl; All elutions were with 1ml of the 
corresponding buffer. 
 
 
Furthermore, the presence of ggapoA-V in the yolk sac was observed using Western blot 
analysis (Figure 3.18, lane 1). The α-ggapoA-V antiserum clearly recognized an 
immunoreactive band of ~40 kDa matching with the well known size for ggapoA-V. The 
presence of ggapoA-V in the yolk sac is in good agreement with the fact that the protein was 
also found in the yolk compartment of chicken follicles (Andrea Dichlberger, unpublished 
results). Whether the detected protein is of maternal origin or synthesized by the cell layers of 
the yolk sac per se is not known. Nevertheless, the presence of the protein in the yolk sac 
supports the notion that ggapoA-V exerts a biological function during development of the 
chicken embryo.  
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Figure 3.18. Western blot analysis of ggapoA-V in the chicken yolk sac. Yolk sac detergent extract 
was subjected to 10% reducing SDS-PAGE and blotted to nitrocellulose membrane. GgapoA-V was 
probed using α-ggapoA-V antiserum (lane 1). Preimmune serum was used as a negative control (lane 
2). For detection of the immunoreactive proteins, HRP-conjugated goat α-rabbit antibody was used, and 
visualization was done using ECL. 
 
 
Several results obtained in my work provide strong evidence that ggapoA-V interacts with 
chicken cubilin in the yolk sac, an important extraembryonic structure which supplies the 
developing embryo with nutrients. Because virtually nothing is known about the function of 
cubilin in the avian yolk sac, it will be interesting to conduct further experiments on this protein. 
In addition, further experiments will be necessary to learn more about the biological importance 
of the ggapA-V – Cubilin interaction. 
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4. DISCUSSION  
 
Apolipoprotein A-V (apoA-V) has been established as an important and potent regulator of 
triglyceride (TG) levels. However, the exact detailed molecular mechanisms involving apoA-V 
are still unknown. Nevertheless, various properties, including the presence on certain classes of 
lipoproteins, lipid binding affinity, lipid droplet association, liver regeneration capacity, and the 
ability to bind cell surface- and sorting receptors have been described for this protein. In regards 
to this latter aspect, a search for new interaction partners of apoA-V is of prime interest.  
Findings in model organisms like the chicken with its highly regulated metabolic pathways for 
TG-rich lipoproteins can be anticipated to be of general significance for our understanding the 
biology of apoA-V. Thus, the capacity of chicken apoA-V to bind to the major oocyte plasma 
membrane receptor LR8 revealed in our group (Dichlberger, Cogburn et al. 2007) provides a 
solid starting point for expanding our research on ggapoA-V in this direction.     
 
4.1. Cubilin, a New Binding Partner of Chicken apoA-V 
 
The major part of my diploma thesis was based on the above mentioned property of apoA-V to 
interact with cell surface receptors. Binding of hapoA-V to LR11, LRP1 and sortilin was reported 
by Nilsson et al using surface plasmon resonance in vitro binding studies for lipid-free as well as 
for DMPC-bound recombinant hapoA-V (Nilsson, Lookene et al. 2007; Nilsson, Christensen et 
al. 2008). They concluded that the protein is able to interact with the ligand binding domains 
present in LDLR related proteins and with Vps10p protein motifs in members of the Vps10p-
domain receptor family. Furthermore, they demonstrated by internalization experiments and live 
imaging studies that hapoA-V is endocytosed by, and co-localizes with, these receptors in early 
endosomes (Nilsson, Christensen et al. 2008).  
Moreover, ggapoA-V was shown to bind the major oocyte receptor LR8 in the chicken 
((Dichlberger, Cogburn et al. 2007) and Figure 3.3). LR8, homologous to the mammalian VLDL 
receptor, is known to mediate chicken oocyte growth by binding and endocytosis of VLDL and 
VTG, the major components of yolk (Bujo, Hermann et al. 1994). Because ggapoA-V was also 
detected in the VLDL fraction of chicken plasma lipoproteins (Dichlberger, Cogburn et al. 2007), 
a proposed function of the protein (maybe in concert with apoB) is to enhance the uptake of 
VLDL particles into the yolk compartment of the oocyte. 
With the evidence that chicken apoA-V shares the receptor binding capacity with its human 
counterpart, I started to search for new binding partners of ggapoA-V in various tissues. Indeed, 
using ligand blot analysis, I was able to detect two new binding partners of ggapoA-V in the 
chicken yolk sac (Figure 3.4, left panel).  
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The chicken yolk sac is an extraembryonic structure consisting of two loosely associated 
somatic cell layers (Figure 4.1). The outer layer is of mesodermal origin, whereas the inner 
layer, facing the yolk compartment, is composed of endodermal cells (Hermann, Mahon et al. 
2000). These cells, called endodermal epithelial cells (EEC’s) mediate the transport of yolk 
components to the embryonic circulation, thereby providing the growing embryo with nutrients. 
The molecular mechanisms underlying these transfer processes are largely unknown. 
Nevertheless, it was reported that the EEC’s express a specific set of receptors which are 
exposed to the yolk compartment. In 2000, Hermann et al reported the presence of LR8 in the 
yolk sac, a highly active lipoprotein receptor with endocytic function (Hermann, Mahon et al. 
2000). Furthermore, current studies have shown that the chicken yolk sac is one of the major 
expression sites of the LDLR-related protein LRP2 (Plieschnig 2008), which has a very broad 
ligand spectrum and also shows high endocytic activity. 
 
 
 
Figure 4.1. Schematic representation of a chicken embryo with its surrounding extraembryonic 
structures. Picture from http://io.uwinnipeg.ca/~simmons/16cm05/1116/chordate.htm 
 
 
Because I could obtain strong evidence that none of the above mentioned receptors are 
interaction partners of ggapoA-V, the identification of the proteins identified by ligand blotting 
with apoA-V (Figs. 3.4 and 3.5) was of great interest.  
The isolation of the >250 kDa ggapoA-V binding partner (Figure 3.5, lane 2) by reverse ligand 
blotting and its subsequent identification as chicken cubilin (Mass Spectroscopy data, Figure 
3.6) provided evidence that ggapoA-V binds cubilin present in the total membrane fraction of 
chicken yolk sac. 
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Structure and ligands of cubilin: Cubilin, which to date has not been characterized in the 
chicken, is a 460 kDa large peripheral membrane glycoprotein in mammals known to be 
involved in endocytic processes (Christensen and Birn 2002). Formerly known as gp280, 
Cubilin was identified in 1997 as the intestinal intrinsic factor vitamin B12 receptor (Seetharam, 
Christensen et al. 1997). The gene for human cubilin is located on chromosome 10p (Kozyraki, 
Kristiansen et al. 1998), and the protein shows a high sequence conservation across species 
(canine cubilin shows 83% identity to human cubilin, (Christensen and Birn 2002)). The 
remarkable structure of cubilin is shown in Figure 4.2. Because cubilin lacks a transmembrane 
region as well as an intracellular domain, the protein is loosely attached to the plasma 
membrane, typical of known peripheral membrane proteins (Kristiansen, Kozyraki et al. 1999). 
The amino-terminal part of cubilin, a stretch of about 130 amino acids, has been shown to 
convey membrane association of the protein (Kristiansen, Kozyraki et al. 1999). Furthermore, 
helical plotting of this region showed the presence of a conserved amphipathic helix structure 
with a similarity to A-type amphipathic helices present in many apolipoproteins (Kristiansen, 
Kozyraki et al. 1999).   
 
 
 
Figure 4.2.  Schematic representation of the overall structural 
composition of cubilin. Cubilin displays neither a transmembrane nor a 
cytoplasmic domain. The protein’s amino terminus, a stretch of about 130 
amino acids, contains a putative class A amphipathic helix region and 
confers membrane association of the protein (Kozyraki 2001). This amino- 
terminal domain is followed by a domain of 8 EGF-repeats and 27 CUB-
domains. This assembly of protein modules observed in cubilin is unique 
among the whole proteome.   
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At the extreme amino terminus of the protein, a recognition cleavage site for the 
transmembrane serine protease furin is present, indicating that post-translational processing of 
cubilin involves furin-mediated cleavage in the trans-Golgi network (Christensen and Birn 2002). 
The amino-terminal stretch is followed by 8 tandemly arranged EGF-type repeats. These 
cysteine-rich protein domains are also present in several membrane proteins including 
members of the LDLR family.   
The largest part of cubilin is comprised of a cluster of 27 CUB (complement C1r/C1s, Uegf, and 
bone morphogenetic protein 1) domains. These CUB domains were initially observed in the 
C1r/C1s components of the complement system (Bork and Beckmann 1993) and subsequently 
in developmental control proteins like spermadhesins, tolloid protein, bone morphogenetic 
protein 1 (BMP1), and the tumor necrosis-factor stimulating protein 6 (TSG6) (Moestrup, 
Kozyraki et al. 1998). Each CUB domain is comprised of 110 amino acids including 4 conserved 
cysteine residues, except domain 13 of Cubilin, which lacks the first 2 cysteines (Moestrup, 
Kozyraki et al. 1998). The crystal structure of the CUB domain has been elucidated in 
spermadhesins (Romero, Romao et al. 1997). There it was shown that the CUB domain is 
composed of 2 five-stranded beta sheets, connected by surface exposed beta-turns (Romero, 
Romao et al. 1997). This predominant structural motif of cubilin has been proposed to constitute 
a potential ligand binding site for interaction with proteins, carbohydrates, and phospholipids 
(Moestrup, Kozyraki et al. 1998).  
Compatible with this notion, cubilin acts as a multiligand binding protein for a broad spectrum of 
ligands including transferrin, albumin, haemoglobin, apolipoprotein A-I/HDL, transthyretin, 
intrinsic factor-vitamin B12, RAP, and for the membrane-anchored receptors LRP2 and 
amnionless (reviewed in Kozyraki and Gofflot 2007). Some of these ligands are also bound and 
endocytosed by LRP2, indicating a synergistic action of these two proteins. 
 
Tissue distribution and intracellular trafficking of cubilin: The major site of cubilin expresssion is 
the surface of various polarized epithelial cells. Therefore, cubilin was shown to be synthesized 
by the epithelial cells of the renal proximal convoluted tubules (PCT), the visceral yolk sac 
(VYS) in rodents, small intestine, and the placenta (Sahali, Mulliez et al. 1988; Seetharam, 
Christensen et al. 1997). In addition, lung alveolar type II cells were reported to express low 
levels of cubilin (Kolleck, Wissel et al. 2002). Although it is well known that cubilin is exposed at 
the plasma membrane of polarized epithelial cells, only little is known about the subcellular 
trafficking and the mechanisms underlying the membrane anchoring of cubilin. However, recent 
studies propose a concerted action of cubilin with the 45- to 50 kDa transmembrane protein 
amnionless for membrane targeting and membrane anchoring of cubilin. In more detail, 
amnionless (AMN) was shown to bind to the EGF domain of cubilin (Coudroy, Gburek et al. 
2005), thereby mediating the release and export of the complex from the endoplasmic reticulum 
(ER) (Coudroy, Gburek et al. 2005).  Furthermore, both proteins seem to be absolutely required 
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for the expression of the complex at the plasma membrane (Coudroy, Gburek et al. 2005). Due 
to its high degree of glycosylation, cubilin is thought to be essential for the apical sorting of the 
receptor complex  (Coudroy, Gburek et al. 2005).  
The essential role of amnionless as a subunit of this receptor complex was also demonstrated 
in a study where cubilin failed to be targeted to the plasma membrane due to a mutation in the 
amnionless gene (He, Madsen et al. 2005). Dogs with this mutation (AMN c.1113-1145del) 
suffered from Imerslund-Gräsbeck syndrome, characterized by intestinal malabsorption of the 
intrinsic factor-cobalamin (vitamin B12) (He, Madsen et al. 2005). Another binding protein of 
cubilin at the plasma membrane is LRP2, which most probably mediates the co-endocytosis of 
cubilin (Moestrup, Kozyraki et al. 1998). This was shown in vitro by a reduced uptake of the 
cubilin ligand HDL following the administration of α-LRP2 antibodies or LRP2 antisense 
oligonucleotides (Hammad, Barth et al. 2000). Figure 4.3 shows the proposed cubilin– 
amnionless–LRP2 trimeric complex. 
 
 
 
Figure 4.3. Cubilin, amnionless, and the large endocytic receptor LRP2 form a trimeric complex 
at the surface of various polarized epithelial cells. Cubilin and amnionless assist each other towards 
successful targeting to the plasma membrane. Additionally, LRP2 binds cubilin, thereby facilitating the 
endocytosis of cubilin ligands (Birn, Fyfe et al. 2000).   
 
 
Physiological role of cubilin:  The first physiological function described for cubilin was the ileal 
absorbtion of intrinsic factor cobalamin (vitamin B12) (Seetharam, Christensen et al. 1997). 
Patients with mutations in the cubilin gene (and also with mutations in the amninonless gene) 
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suffer from the Imerslund-Gräsbeck disease (also known as autosomal recessive megaloblastic 
anemia, MGA), characterized by malabsorption of cobalamin (vitamin B12).  
In the kidney, high expression levels of cubilin were shown to contribute to the reabsorption of 
low molecular weight proteins such as albumin and apoA-I. This was again observed in dogs 
which lack functional cubilin. These dogs excrete high amounts of known cubilin ligands with 
their urine (Kozyraki, Fyfe et al. 1999; Birn, Fyfe et al. 2000), which is also the case for humans 
suffering from the Imerslund-Gräsbeck disease.   
Finally, cubilin is known to be abundantly expressed in the visceral layer of the rodent yolk sac 
(Sahali, Mulliez et al. 1988). An indirect evidence for the physiological importance of cubilin at 
the feto-maternal interface was provided by the finding that the administration of monoclonal α-
cubilin antibodies induced fetal resorption or malformations (Sahali, Mulliez et al. 1988). One 
reason for this dramatic phenotype could be the reduced or impaired uptake of cholesterol due 
to the functional inactivation of cubilin, shown to be responsible for the uptake of apoA-I/HDL in 
yolk sac epithelial cells (Kozyraki, Fyfe et al. 1999). Another function of cubilin at the feto-
maternal interface was found by a research group studying the biology of uterine lectins. Quite 
surprisingly, they found that the lectin galectin-3 in the murine utero-placental complex, a 
protein found exclusively in the uteri of pregnant females and mainly located at the implantation 
site of the embryo, interacts with cubilin (Crider-Pirkle, Billingsley et al. 2002).  
Interestingly, to date there have been no reports about cubilin in any avian species. However, 
the findings reported here, i.e., that ggapoA-V binds chicken cubilin in the chicken yolk sac, 
provides even more evidence for the functional importance of cubilin at feto-maternal interfaces. 
Chicken yolk sac, which functions analogous to the mammalian placenta, absorbs components 
from the yolk compartment to provide the chicken embryo with essential nutrients. Compared to 
other species, it is likely that this uptake is mediated via endocytic receptors, which localize to 
the surface of the EEC layer of the yolk sac. The finding that LRP2 is one of these receptors 
(Plieschnig 2008) makes the presence of cubilin in the chicken yolk sac even more interesting. 
Therefore, it is most likely that in the chicken yolk sac, cubilin and LRP2 also act as a highly 
efficient endocytic complex. In addition, chicken amnionless transcripts were detected by 
Northern blot analysis in the yolk sac (Christian 2006). The expression of ggAMN and the 
presence of cubilin and LRP2 proteins in the yolk sac suggest that an active trimeric complex is 
produced in this tissue. Nevertheless, because we have only very limited information about the 
amnionless protein in chicken yolk sac, further investigations are required to characterize the 
cubilin-amnionless-LRP2 complex in the chicken.       
Furthermore, the ggapoA-V–cubilin interaction in the yolk sac is supported by at least two 
interesting observations. First, Western blot analysis showed that ggapoA-V is present in the 
yolk compartment of growing follicles (Andrea Dichlberger, unpublished reults). Secondly, 
ggapoA-V could also be detected in yolk sac extracts (Figure 3.18).  These findings are 
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compatible with the uptake of ggapoA-V into cells of the yolk sac via cubilin as part of the 
trimeric cubilin-amnionless-LRP2 complex, but this possibility needs to be tested formally.   
Figure 4.4. shows a proposed model for the migration and/or transport of ggapoA-V from its site 
of synthesis in the maternal liver to its endocytosis by cubilin into cells of the yolk sac. After its 
synthesis, ggapoA-V leaves the liver either bound to VLDL and HDL particles or in lipid-free 
form. At the plasma membrane of the growing oocyte, ggapoA-V binds to and is internalized by 
LR8 into the yolk compartment of the germ cell. After fertilization of the oocyte, embryonic 
structures begin to form. During embryogenesis, yolk becomes enclosed by two cell layers 
giving rise to the extraembryonic structure of the yolk sac. These cells, most probably the EECs,  
express cubilin at the surface facing the yolk compartment. Consequently, ggapoA-V becomes 
bound and endocytosed, resulting in its localization in the cells of the yolk sac. Whether 
ggapoA-V is targeted to the embryonic circulation or fulfills a hitherto unknown function in the 
cell layer of the yolk sac is not known. However, the EEC layer of the chicken yolk sac is highly 
enriched in phagolysosomes containing yolk granules (Donaldson, Bogenman et al. 1990). 
These yolk droplets contain lipids and apolipoproteins, which were previously taken up by the 
EECs from the yolk compartment (Kanai, Soji et al. 1997). The fact that apoA-V was shown to 
associate with lipid droplets (Shu, Ryan et al. 2008) suggest the presence of ggapoA-V within 
the yolk granules of the yolk sac EECs. There, the protein could be used for the synthesis of 
new lipoprotein particles, which are subsequently transferred to the embryonic circulation to 
supply the embryo with nutrients (Kanai, Soji et al. 1997). Interestingly, early studies suggested 
that apoA-V may be a limiting factor for the production of triglyceride-rich lipoproteins 
(Dichlberger, Cogburn et al. 2007); thus, sufficient amounts of apoA-V may be provided via the 
multi-step process described here. 
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Figure 4.4. Schematic representation of the proposed metabolic pathway of ggapoA-V. GgapoA-V 
(green) enters the maternal circulation after its synthesis in the liver. At the plasma membrane of the 
oocyte, the protein is endocytosed by LR8 and accumulates in the yolk compartment of the oocyte. After 
fertilization and formation of the yolk sac, ggapoA-V is internalized into the EEC layer of the yolk sac by 
an uptake mechanism involving the peripheral membrane protein cubilin. 
 
 
As determined by Western blot analysis, yolk sac cubilin showed a slightly slower migration in 
SDS gels (Figure 3.14) than kidney cubilin. One of the reasons for this difference could be a 
tissue specific, alternative posttranslational modification of the protein. Two mechanisms by 
which cubilin is posttranslationally modified are cleavage of the cubilin leader peptide by the 
TGN proteinase furin and glycosylation of the protein, as cubilin was shown to contain 42 
potential N-glycosylation sites (Moestrup, Kozyraki et al. 1998). Differences in the glycosylation 
pattern between yolk sac- and kidney cubilin could also contribute to different binding affinities 
of ggapoA-V to cubilin. This may explain why ligand blot analysis detected the binding of 
ggapoA-V to cubilin present in yolk sac extracts only.  
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In conclusion, the results gained during my diploma research provided strong evidence for the 
identification of cubilin as a new binding partner of ggapoA-V, and allows the proposal of a 
model for the action of cubilin in the chicken yolk sac. The newly generated data are a solid 
basis for further studies into the functions of apolipoproteins and their receptors in the chicken, 
which is a powerful model due to the highly regulated pathways orchestrating massive lipid flow 
in the laying hen. 
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6. ABBREVIATIONS 
 
A            
 α   alpha, anti 
 α-2M   alpha-2 macroglobulin  
 A   adenin 
 Apo   apolipoprotein 
 APS   ammonium persulfate 
 Amp   ampicillin 
 AMN   amnionless    
B            
 BMP1   bone morphogenetic protein 1 
 bp   base pair  
C            
 C   cytosine 
 CE   cholesterolester 
 CM   chylomicrons 
 cDNA   complementary DNA 
 CaCl2   calcium chloride 
 C-terminus  carboxy-terminus 
 CD   circular dichroism 
 CUB   complement C1r/C1s, Uegf, and bone morphogenetic protein 1 
 CNBr   cyanogen bromide 
D            
 DNA   deoxyribonucleic acid 
 DTT   dithiothreitol 
 DMPC   dimyristoil phosphatidylcholin  
E            
 EDTA   ethylenediaminetetraacetic acid 
 ECL   enhanced chemiluminescence 
 ER   endoplasmic reticulum 
 EEC   epidermal endothelial cells 
 EGF   epidermal growth factor   
G            
 G   guanine 
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 gg   gallus gallus 
 GC   granulosa cells 
 GPIHBP1  glycosylphosphatidylinositol-anchored high-density lipoprotein 
    – binding protein 1 
 gp   glycoprotein  
H            
 HDL   high-density lipoprotein 
 HRP   horseraddish peroxidase 
 HNF4A   hepatocyte nuclear factor-4 alpha 
 HSPG   heparan sulfate proteoglycane 
 hs   homo sapiens 
 His   histidine 
 hr   hour 
I            
 IPTG   isopropyl β-D thiogalactoside 
 IL 1-B   interleukine 1-beta 
 IP   immunoprecipitation 
 IgG   immunoglobulin G 
 IF   intrinsic factor  
K            
 kDa   kilo dalton 
 kb   kilo bases 
 kbp   kilo basepairs  
L            
 LDL   low-density lipoprotein 
 LRP   low-density lipoprotein receptor related protein 
 LB   luria broth 
 LCAT   lecithin:cholesterol-acyltransferase 
 LDLR   low-density lipoprotein receptor 
 LR8   low-density lipoprotein receptor related protein with 8 ligand 
    binding domains 
 LPL   lipoprotein lipase 
 LA   type A ligand binding domains 
 LH   laying hen 
 LXRA   liver X receptor alpha  
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M            
 µ   micro 
 mM   milli molar 
 mA   milli ampere 
 MWCO   molecular weight cut-off 
 mRNA   messenger ribonucleic acid 
 MTP   microsomal transfer protein 
 Mm   mus musculus 
 M6P   mannose-6-phosphate 
 MGA   megaloblastic anemia  
N            
 nm   nano meter 
 n.d.   not defined 
 NTP   nucleoside triphosphate 
 N-terminus  amino terminus 
 Ni-NTA   nickel nitriloacetic acid   
O            
 o.n.   overnight 
 OD   optical density 
P            
 PCR   polymerase chain reaction 
 PBS   phosphate-buffered saline 
 PAA   polyacrylamide 
 PPARA   peroxisome proliferator-activated receptor alpha 
 PCT   proximal convoluted tubule 
 PAGE   polyacrylamide gel electrophoresis 
R            
 RT   room temperature 
 rpm   rounds per minute 
 RNA   ribonucleic acid 
 R/O   restricted ovulator 
 RAP   receptor associated protein 
 RT-PCR  reverse transcriptase polymerase chain reaction 
S            
 SDS   sodium dodecyl sulfate  
 SNP   small nucleotide polymorphism 
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 SPR   surface plasmon resonance 
T            
 TG   triglyceride 
 T   thymine 
 TEMED   N,N,N',N'-Tetramethylethylenediamine 
 TBS   tris-buffered saline 
 TNF-α   tumor necrosis factor-α 
 TGN   trans-golgi network 
 TSG6   tumor necrosis-factor stimulating protein 6 
U            
 UV   ultra violette 
 USF1   upstream-stimulating factor 1  
V            
 VLDL   very-low density lipoprotein 
 Vps10p   vacuolar protein sorting 10 protein 
 VTG   vitellogenin 
 VBC   Vienna Biocenter 
 VYS   visceral yolk sac 
Y            
 YS   yolk sac 
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